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HOW MUCH ANXIETY 
"There is a common tendency in our day, both 
on the part of professional psychologists and laymen, 
to look upon anxiety as a negative, destructive, 
"abnormal" experience, one which must be fought 
and if possible annihilated .... " 
0. H. Mowrer' 
Since 1950 the literature on anxiety, both 
professional and lay, has increased a thousandfold in 
the form of articles, symposia, reports and scientific 
exhibits. And virtually all of this output reflects a 
common presumptiol}-that anxiety is a negative, 
nonproductive experience. This viewpoint leads nat-
urally to a discussion of how to combat or eliminate 
anxiety. 
But anxiety, as Mowrer implies, has its uses. 
It can play a positive and constructive role in human 
development. Without it neither an individual nor a 
society can grow. 
Productive vs. 
nonproductive anxiety: 
a matter of degree 
For the physician the difference is not an 
academic one. He must distinguish between produc-
tive and nonproductive anxiety. And the difference 
is often one of degree. 
In low levels of anxiety, for example, the indi-
vidual is alert and sensitive to threats and acquires 
an increased ability to cope. Performance is often 
improved.2 
But at higher levels of anxiety the opposite is 
true.2 The ability to distinguish between the danger-
ous and the trivial is reduced and often leads to 
inappropriate behavior. Apprehension becomes fear. 
And coping becomes difficult, if not impossible. 
Crossing the 
anxiety threshold 
The key question for the physician then be-
comes: Is the degree of anxiety experienced produc-
tive or nonproductive for the individual patient? 
And while some patients may require relatively large 
amounts of anxiety to perform optimally, for others 
lower levels of anxiety may prove unproductive. 
Librium®(chlordiazepoxide 
HCI): to help lower 
the level of anxiety 
When anxiety has reached levels that seriously 
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impair performance, reassurance and counseling 
may be sufficient for the patient. If not, adjunctive 
antianxiety medication may be called for. 
Librium (chlordiazepoxide HCl), by quickly 
and effectively calming the anxious patient, helps to 
lower the level of anxiety. When anxiety has been 
reduced to manageable levels, therapy with Librium 
should be discontinued. 
Librium®(chlordiazepoxide 
HCl):an 
uncomplicated clinical course 
To be truly effective, antianxiety medication 
must allay anxiety without complicating the clinical 
course. Librium meets this criterion. Librium, when 
used in proper dosage, rarely interferes with mental 
acuity. Side effects are seldom encountered. And 
Librium is used concomitantly with many primary 
medications. 
For a more detailed discussion of the side 
effects, precautions and warnings, please consult the 
brief summary of product information on this page. 
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INTRODUCTION 
During my residency at the University of Chi-
cago twenty years ago, I performed the few diagnostic 
studies employing radioactive isotopes as a "side-
line," spending a couple of hours each day in the 
laboratory. Nuclear Medicine since then has grown 
into a vast field incorporating in vitro studies, in vivo 
procedures, and treatment with radioactive isotopes. 
The continued development of new isotopes 
is presenting us with new techniques. Some of these 
isotopes have such a short half-life that they have 
to be produced locally, and their purity and concen-
tration have to be controlled by a radiopharmacist 
who has become a team member of all larger nuclear 
medicine divisions. 
The equipment detecting the radiation emerging 
from these isotopes has become much more sophisti-
cated, and the quality of the images produced during 
scanning procedures approaches that of radiographs. 
But imaging has changed from being a simple 
reflection of normal or pathological morphology to a 
method of dealing with abnormal physiology. Dy-
namic computer-assisted scanning of the heart, for 
example, can tell us.today whether myocardial damage 
is irreversible, and multiple sequential scans can 
demonstrate an arteriovenous shunt of the brain. 
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It is not astonishing that in this rapidly progress-
ing field even the expert might lose sight of the latest 
developments, and this is the reason why the De-
partment of Radiology of the Medical College of 
Virginia felt it would be appropriate to present a 
program on Nuclear Medicine during our Annual 
Postgraduate Course Series in Williamsburg. We 
were fortunate in attracting an outstanding faculty 
which agreed to undergo the additional workload of 
editing selected papers presented in Williamsburg for 
publication in this and the forthcoming issue of the 
MCV Quarterly. 
I would like to congratulate my colleagues for 
their superb contributions to the Quarterly. I would 
like to thank Ors. Ghahremani and Sharpe who so 
ably organized the Postgraduate Course and express 
my special appreciation to Ms. Mary-Parke Johnson, 
the Managing Editor of the MCV Quarterly, for her 
support and editorial assistance. 
KLAUS RANNIGER, M.D. 
Professor and Chairman 
Department of Radiology 
Radiopharmaceutical Production and 
Quality Control* 
JERRY I. HIRSCH, PHARM. D. 
Assistant Professor of Radiology and Pharmacy, Medical College of Virginia, Health Sciences Division oj 
Virginia Commonwealth University, Richmond, Virginia 
With the development of shorter-lived, organ-
specific radiophatmaceuticals, much of the manufac-
ture and quality control of these products have 
shifted from commercial manufactures to individual 
nuclear medicine laboratories. Recognizing this fact, 
the Nuclear Regulatory Commission (NRC) is en-
couraging quality assurance by proposing that "an 
authorized physician may permit technicians and 
other paramedical personnel to perform the prepara-
tion and quality control testing of radiophar-
maceuticals ... " (1). 
Cohen (2) has catagorized pharmaceutical con-
trols into chemical, biological, and physical. Figure 1 
is a diagram of these controls. In each control a 
degree of purity is implied and is often determined by 
comparison to a standard. 
Chemical controls. 
A. Radiochemical purity. May be defined as that 
portion of the stated radionuclide in the stated 
chemical form. This can be assessed in the nuclear 
medicine laboratory by several techniques. It is ap-
plicable to Tc99m-pertechnetate compounds where 
the degree of tag to an organ-specific molecule must 
be evaluated. 
Radiochemical impurities may be demonstrated 
in those images where organs other than the target 
organ are visualized due to a free (unbound) radioac-
tive component of a labeled product. Visualization of 
thyroid on lung imaging (Fig. 2) or stomach with 
kidney (Fig. 3) and bone (Fig. 4) imaging are exam-
ples of these. Reagent "kits" labeled with 
* Presented by Dr. Hirsch at the Postgraduate Course in Nuclear 
. Medicine, February 25, 1975, in Williamsburg, Virginia. 
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radionuclides should be at least 90% bound for op-
timum organ visualization. The assessment of 
binding can be accomplished in the laboratory 
by the use of gel filtration and/or thin-layer 
chromatographic techniques. Labeled reagent kits 
may contain small molecules (free Tc99m-
pertechnetate), larger labeled molecules, and a 
reduced technetium fraction which is considered 
neither free nor bound to an organ-specific molecule. 
To determine the percentage of each component in 
this three-phase system by employing the gel filtration 
technique, 1-2 µl of the material is placed at the top 
of a gel column and eluted with a suitable solvent. 
Heavy molecules which do not enter the gel mesh-
work will be eluted first, after the void volume. Light 
molecules will follow several milliters later. Reduced 
technetium, if present, will bind to the gel and can 
be removed by oxidation with 0.1 % H202. This frac-
tion can be subsequently collected with additional 
volumes of solvent. The fractionated volumes are 
counted and quantitation of each component may be 
determined. 
Thin-layer chromatography employs the use of 
suitable media strips to which is spotted 5µ1 of the 
radioactive material 2.5 cm from the bottom of the 
strip. The strip is dried and placed in a developing 
tank containing a suitable solvent system (Fig. 5). 
The solvent is allowed to ascend the strip until the 
front is at approximately 14 cm. Solvent systems 
chosen provide for the bound material to remain ap-
proximately at the origin (point of application) while 
free activity migrates to the level of the solvent front. 
Using this method, Rf (reference factor) may be 
determined. These factors are ratios of distance 
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Chemical 
controls 
e Radiochemical 
purity 
e Carrier 
amount 
e Sterility 
Physical 
controls 
• Radioactive 
concentration 
e Apyrogenicity e Radioactive 
purity 
e Buffer amount e Safety 
e Total ions e Affinity 
concentration 
Fig. I-Diagram of the radiopharmaceutical controls. 
traveled by the radioactive entities to that traveled 
by the solvent front. Labeled molecule Rf are approx-
imately 0-0.1 while that of free species 0.8-1.0. Sol-
vent systems may be single or multiple components 
and provide for good separation of labeled molecules 
and free ionic species. 
Strips are removed from developing tanks, air 
dried, and analyzed for quantitation of components 
in the sample. Strips may be cut into 1 cm widths and 
placed into gamma well counters to determine 
presence and, therefore, identity of activity on the 
strip. The origin (2.5-3 .5 cm) of acceptable 
radiopharmaceuticals contains 90% of the counts. A 
radiochromatogram well adapter can be used and is 
less time consuming (3). Radioscanchromatographs 
can provide this information by producing a graph 
with peaks of activity demonstrating location and 
quantitation of radioactive components. 
Figure 6 is a chromatograph of Tc99m-
Polyphosphate® (New England Nuclear) used as the 
bone scanning agent in Figure 4. The chromatograph 
demonstrates activity at the origin representing 
Fig. 2-1'"-macroaggregated albumin (Abbott) lung image 
demonstrating thyroid uptake of free radioiodine. 
Fig. 3-Tc••m-Renotec (Squibb) kidney image demonstrating 
stomach uptake of free Tc••m-pertechnetate. (Image provided 
courtesy Dr. H. T. Haden, McGuire VA Hospital, Richmond, Va.) 
Tc99m-pertechnetate bound to phosphate complexes, 
activity between origin and solvent front demonstrat-
ing reduced pertechnetate and/ or labeled metabo-
lized phosphates, and a second but less prominent 
R 
• 
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J.C. 8-9-74 
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I I 
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J.C. 8-9-74 
R 
Fig. 4-Tc••m-Polyphosphate® (New England Nuclear) bone im-
age demonstrating stomach uptake of free Tc99m-pertechnetate. 
Increased activity in liver probably associated with a reduced 
technetium species in blood pool. 
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Recommended Chromotography Sol vents 
Rf 
Pree:arotion Solvent BTc FTc 
Tc99m (Sn) DTPA Acetone 0.0 1.0 
Butyl acetate o.o 0 . 8 
Tc99m (Sn ) Gluco-
heptonate M.E . K. 0.0 1.0 
·Tc99m - HSA Methanol, 85% o.o 0 . 8 
Tc99m - MAA Methanol, 85% 0.0 0.8 
Tc99m - Polyphosphate Acetone 0.0 1.0 
Butyl acetate 0.0 0.8 
Renotec * Butanol : Ethanol : Water 0 . 1 0.7 
(2 :2: 1) 
Tc99m - Sulfur Colloid Methanol, 85% 0. 1 1. 0 
*Eastman TLC Cellulose H6064 media; all others , Gelman ITLC 
Type SG 
Fig. 5-Chromatography solvent systems recommended for the 
determination of bound (BTc) and free (FTc) components of 
technetium-99m kit preparations. Each system provides reproduci-
ble Rf values used in the identification and quantitation of each 
component. 
peak at the solvent front demonstrating free 
pertechnetate. 
Figure 7 compares the chromatographs ofTc••m_ 
Polyphosphate® (NEN) to that of Osteoscan® (Proc-
tor and Gamble). Technetium-99m-pertechnetate ob-
tained from a 400 millicuries fission Mo99-Tc99m 
generator. was used to prepare each of the above bone 
imaging agents. The Tc••m-Polyphosphate® chromat-
ogram demonstrated 98.5% of the pertechnetate 
bound to the phosphate complex. With Osteoscan®, 
the chromatograph demonstrated a reduced and/ or 
labeled metabolized phosphate component of approxi-
mately 40%. The manufacturer claimed that the ni-
trogen atmosphere in the vial was lost through the 
rubber closure with oxidation of the Sn(II) reducing 
agent. (Recently the manufacturer has adopted a 
butyl rubber closure which has resolved this problem.) 
Figure 8 is a chromatograph of Tc••m-Sn-
Glucoheptonate® (NEN). With methyl ethyl ketone 
(MEK) solvent, peak activity was found at the 
origin corresponding to the bound component. No 
free pertechnetate was demonstrated. The manu-
facturer claimed the material may be subject to col-
loid formation with some resultant localization of 
activity in the liver. The material was chromato-
gramed in a physiologic saline solution demonstrat-
ing no colloid at the origin. 
B. Carrier amount. May be defined as stable or 
long-lived isotopes of the nuclide present at the time 
of administration of the radiopharmaceutical. Car-
rier, if present in large quantities, alters the distribu-
tion of the nuclide in vivo or adds to radiation burden 
if it is radioactive. Manufacturers prepare com-
pounds that are "carrier-free." This has come to 
mean that no other isotope of the nuclide has been in-
tentionally added. 
C . Buffer amount. The pH of radiophar-
maceuticals should be adjusted to provide for stable 
complexes as well as physiologic suitability. Most 
radiopharmaceuticals are adjusted in the range of pH 
4.0 to 8.8. 
D. Total ions concentrations. Radiochemical 
solutions after production may contain various 
metals or metaloids as contaminants. These contami-
nants may be imparted from apparatus and reagent 
materials even if very pure. Complexation of the 
radiochemical with these traces give chemically un-
stable radioactive solutions. A standard of 80µg / ml 
of these ions has been set; however, the current state 
of the art is to prepare products with less than 
lµg / ml. 
Of the potential nonradioactive ionic impurities 
present in Tc••m-pertechnetate eluent, aluminum [Al 
(III)] has produced the most concern. Toxicology of 
Al (III) of potential doses administered appears 
minimal (Fig . 9); however, it has been reported to 
cause flocculation of Tc99m-sulfur colloid prepara-
tions as well as agglutination of red blood cells during 
the labeling process (4). Current NRC standards limit 
the presence of this ion to lOµg (fission Mo"") and 
20µg (activation Mo"") per milliliter of generator 
>-
f-
80 
60 
> 4 0 
i= 
u 
<{ 20 
Tc99m- POLYPHOSPH ATE 
METHANOL 85% 
CENTIMETERS 
Fig. 6.-Chromatograph ofTc99m-Polyphosphate® used to produce 
bone image in Figure 4 demonstrates bound, reduced, and free 
components of the radiopharmaceutical. 
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COMPATIBILITY OF KIT SOURCE AND RADIONUCLIDIC BINDING EFFICIENCY 
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Fig. 7-Comparison of chromatographs obtained after preparation of two commercially available bone imaging agents; Tc"m-Polyphos-
phate® (New England Nuclear), Tc"m-Osteoscan® (Proctor and Gamble) . 
eluent. This represents a more stringent requirement 
from a previous 500µg Al (III)/10 millicuries Tc99m-
pertechnetate limitation . 
To determine at what concentration of Al (Ill) 
flocculation of sulfur colloid would occur, Al (III) 
solution was prepared by dissolving 99+% aluminum 
metal in HCI. Aluminum (lll)-Tc99m-pertechnetate 
solutions were prepared such that Al (Ill) concentra-
tion ranged from lOµg/ml to lOOOµg/ml of Tc99m-
pertechnetate in saline (Fig . 10). A control using Al 
(lll) free pertechnetate was also prepared. Tech-
netium-99m-sulfur colloid (Squibb) were prepared 
by standard methods incorporating each of the Al 
(lll)-Tc99m-pertechnetate solutions as the radioactive 
source. Final sulfur colloid volumes were 8 ml giving 
resultant Al (III) concentrations of 0 to 12.50 mg%. 
Aluminon reagent (aurin-tricarboxylic acid) test 
strips (NEN) were evaluated for suitability in the 
detection of Al (Ill) contamination at levels as-
sociated with sulfur colloid flocculation (Fig. 11 ). 
Colloid aggregation was determined by placing 0.1 
ml of each sample on a standard hemocytometer 
chamber and observation under light microscopy 
(Fig. 12). 
Two hundred microcuries (0.2 ml) of each of the 
sulfur colloid preparations were injected into 250 g 
female Sprague-Dawley rats via a femoral vein. Scin-
tiphotos were obtained using the Searle Radio-
graphies .Pho-Gamma HP camera fitted with a pin-
hole collimator to demonstrate distribution of the 
radiocolloid (Fig . 13). 
Preparations of sulfur colloid from 0 to 0.63 
mg% Al (III) demonstrated no aggregation . Alumi-
non test papers demonstrated an increase in the pres-
ence of Al (III) with each increase in ion concen-
tration . Scintiphotos of test animals demonstrated 
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BINDING EFFICIENCY Tc99m-Sn-GLUCOHEPTONATE (N.E.N.) 
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Fig. 8-Chromatographs obtained following development of Tc••m-Sn-Glucoheptonate® (New England Nuclear) in two solvent systems. 
Upper chromatograph demonstrates absence of free pertechnetate. Lower chromatograph demonstrates absence of colloid. 
distribution of radiocolloid to liver with no uptake in 
lung. At 0.94 mg% Al (III), some colloid aggregation 
was present with minimum uptake of colloid in the 
lung of test animal. At 1.56 mg% Al (III), aggregate 
size became critical with scintiphotos demonstrating 
significant quantities of radiocolloid in lung. Lung 
uptake of radiocolloid increased at 3.13 mg% Al (III). 
Test materials containing 6.25 mg% and 12.50 mg% 
Al (III) demonstrated larger aggregates; however, 
these materials were not administered to test animals 
because aggregates would be limited to the inside 
diameter (254µ) of the 25 G needle. 
Liver, lung, and spleen from each test animal 
were excized and counted using a Picker well counter. 
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TOXICOLOGY ALUMINUM CONTAMINATION IN 
PERTECHNETATE 
A.E.C. LIMIT - lOµg./ml. NaTc04 
I. V. LD50 OF ALUMINUM (AS AICl 3) IN MICE IS 
79 mg./Kg. (EQUIVALENT TO ABOUT 20 mg. 
ALUMINUM/Kg,) 
l.V. LD2 OF ALUMINUM (AS AICl3) IN MICE IS 
55 mg ./Kg. (EQUIVALENT TO 14 mg. ALUMINUM/Kg.) 
Fig. 9-Nuclear Regulatory Commission (AEC) allowable limit 
for aluminum ion contamination in Tc99m-pertechnetate. Limit is 
within a margin of safety for administration to man. 
Ratios of counts for liver: lung and liver: spleen were 
calculated (Fig. 14) and demonstrated good correla-
tion with Squibb Institute reports for the control 
material. At Al (III) concentration of 0.13 mg% to 
0.94 mg%, there was a general increase in liver: lung 
with a corresponding general decrease in liver: spleen. 
Sulfur colloid used in liver imaging vary in size from 
mµ to 1 µ. Up to 15% of the material may normally 
localize in bone marrow attributable to the smaller 
end of colloid size range. With increasing concentra-
tions of Al (III), smaller colloid may aggregate 
providing for more liver localization . Similarly, as the 
colloid size continues to increase, more of the 
material may localize in spleen, which is capable of 
phagocytizing colloid larger than that by liver. 
At the critical concentration of 1.56 mg% Al 
(Ill), liver: lung was 0.32: 1 demonstrating on a per-
gram basis three times the activity of radiocolloid in 
lung as compared to liver. At 3 .13 mg% Al (III), ac-
tivity in the lung increased to 16 times that of liver. 
~ µ.g. Al+ 3/ml. Tc99m04 (mg. %) µ.g. Al + 3/ml. Kit* (mg. %) 
' 
10 10 (1. 0) 1.25 (0.13) 
25 25 (2.5) 3.13 (0.3 1) 
50 50 (5 .0) 6.25 (0.63) 
75 75 (7.5) 9.38 (0.94) 
125 125 (12.5) 15.63 (1.56) 
250 250 (25.0) 31.25 (3.13) 
500 500 (50.0) 62.50 (6.25) 
1000 1000 (100.0) 125.00 (12.50) 
• FINAL PREPARATION = 8 ml. 
Fig. IO-Concentration of aluminum ion in radioactive solutions. 
Center panel expresses aluminum concentration present in Tc99m-
pertechnetate. Third panel expresses aluminum concentration 
present following preparation of sulfur colloid kit. 
Aluminum Ion Spot Test 
Aluminon Reagent Paper 
Control 
125pgAl+3 /ml. 
250pgAl+3 /ml. 
500pgA1+3 /ml. 
1000pgAl+3 /ml. 
STq 
IOpg Al 3/ml. 
Fig. I I-Change in aluminon spot test with increasing concentra-
tion of aluminum ion. 
In conclusion, the Aluminon test papers were 
adequate in detecting Al (III) concentration, and the 
maximum allowable concentration of Al (III) in 
Tc99m-pertechnetate was found to be 75µg/ml. The 
current standard is well within this value. 
Biological Controls. The United States Phar~ 
macopeia (USP) specifications for all parenteral 
products includes the absence of viable forms of 
bacteria, viruses, yeast, and molds as well as 
pyrogenic substances. Therefore, radiopharmaceuti-
cals administered parenterally must also be of this 
quality. 
A. Sterility. Many of the radiopharmaceuticals 
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Tc99m - SC 
Fig. 12-Effect of increasing concentration of 
aluminum ion on colloid aggregation. Magni-
fication is IOX. 
Representative of 
0 -0.63mg.0/oAl+3 
l.56mg.0/oAl+3 
6.25 mg.0/oAl+3 
1--1 
50)J 
0.94mg.0/oAl+3 
3.13mg.0/oAl+3 
12.50mg.0/oAl+3 
64 
Omg. 0/o A1+3 
0.31mg.0/oAl+3 
0.94mg.0/oAl+3 . 
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0.13mg. 0/oAl+3 
0.63mg.0/oAl+3 
1.56 mg. 0/o A1+3 
Fig. 13-Effect of increasing con-
centration of aluminum ion on 
radiocolloid distribution in rat. 
Anterior views obtained with 
Searle Radiographies-HP gamma 
camera fitted with a pin-hole 
collimator. Each image represents 
the accumulation of 100,000 
counts. 
3.13mg.0/oAl+3 
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Effect of Al+3 Content in Tc99m - Sulfur Colloid on 
Distribution Ratios* in Rat 0 rgans (per gram wt.) 
mi;i. % Al+3 Liver: Lung Liver: Spleen 
0 4.73:1 1.23:1 
o. 13 6.73:1 6.43:1 
0.31 5.23:1 4.77:1 
0.63 3.46: 1 1. 83:1 
0.94 4 . 81:1 1.59:1 
1.56 0.32:1 1.16:1 
3.13 0.06: 1 0.37:1 
* 20 min. post-injection (i.v.) 
Fig. 14-Ratios ofliver:lung and liver:spleen counts obtained from 
excized rat organs. Ratios are expressed per-gram weight of organ. 
used as diagnostic agents in nuclear medicine are in-
tended for parenteral administration . Phar-
maceuticals of this type must meet USP requirements 
in that they are sterile, apyrogenic, and of acceptable 
pH (5). 
Methods of sterilization vary and selection is 
dependant upon stability of the compound and its 
label. Terminal sterilization in an autoclave and 
membrane filtration are two of the more commonly 
used methods employed to sterilize radiophar-
maceuticals. With each of the above methods, 
however, samples must be taken and tested to con-
firm sterility. 
The USP method requires innoculation of the 
radiopharmaceutical into fluid thioglycolate and 
Soybean-Casein Digest medias. A 7-day incubation 
period at 30 to 35°C with fluid thioglycolate and 20 to 
25°C with Soybean-Casein Digest without evidence of 
viable organisms indicates a sterile preparation. It 
becomes apparent that activity of radiopharmaceuti-
cals with short physical half-lives would significantly 
decay before the product was approved for clinical 
use. Under this circumstance, the dilemma of whether 
to administer the preparation may be minimized if 
asceptic technique were employed and previous 
materials tested after-the-fact demonstrated sterility. 
Work by Deland and Wagner (6) has shortened 
the determination of sterility to within acceptable 
time for short-lived nuclides. Test materials are in-
noculated in thioglycolate broth containing C'4 
glucose. Viable organisms, if present, would 
metabolize the labeled sugar to C'40 2 which is 
detected and recorded, demonstrating the presence of 
microbial contamination. This procedure, although 
not an official test, has reduced lag time from days to 
1-3 hours. 
B. Apyrogenicity . Pyrogens of microbial origin, 
are mucopolysaccharide molecules present as the 
result of bacterial, viral, fungal , or yeast contamina-
tion. The substances are heat-stable and therefore 
resistant to destruction by terminal sterilization. 
When administered by some injection route, they 
may produce in man such symptoms as mono-or 
biphasic fever, chills, malaise, mild to moderate pain 
in the joints, and leukopenia, or other less well-defined 
clinical signs, such as apprehension, pallor, and sub-
sternal oppression (7). Sensitivity of the human body 
to administration of pyrogens by the intrathecal 
route is such that the biologic insult of this type in-
creases 4000-fold as compared to the intravenous 
route (8). 
The USP method for the detection of pyrogens 
relies upon rectal temperature change in the pre- to 
post-innoculated rabbit. Controls for the test are 
stringent and include: 
I. Use of healthy, mature rabbits each weighing 
not less than 1.5 kg that have maintained this 
weight for one week. 
2. Control temperature of each rabbit used does 
not vary by more than l °C from each other. 
No animal may be used with a control 
temperature exceeding 39.8°C. 
3. Animals must be housed individually, free 
from excitement, in an environmental tem-
perature that does not vary by more than 
± 3°C. 
4. Animals may not be used more than once 
every 48 hours. 
5. Animals may not be used before 2 weeks hav-
ing been given a test sample that was 
pyrogenic. 
6. Animals not used for pyrogen testing during a 
14-day period must be sham tested 1-3 days 
before use. 
7. Test material administered may not exceed 10 
ml. 
Test material is injected into the marginal ear 
vein of three animals. Rectal temperatures are 
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recorded at hourly intervals for three hours post in-
jection. If none of the test animals show an individual 
temperature rise of 0.6°C or more above its control 
temperature and ifthe sum of the temperature rises in 
all three animals does not exceed l.4°C, the test 
material meets the requirement of apyrogenicity. If 
the above criteria are not met, the test must be 
repeated with five rabbits. If not more than three of 
the eight rabbits show temperature rises of 0.6°C or 
more and if the sum of the eight temperature rises 
does not exceed 3.7°C, the product under test meets 
the requirement for apyrogenicity. 
Pyrogen testing by the USP method is difficult, 
time consuming, and generally not amenable to small 
laboratories. Cooper et al (9), have introduced an in 
vitro test based on the detection of endotoxin 
through gelation of Limulus polyphemus lysate 
prepared from blood amebocytes. Test results may be 
obtained in 1 hour which represents time saved with 
respect to short-lived nuclides. This test is signifi-
cantly more sensitive than the official test; however, it 
is subject to false positive results if the preparation to 
be tested contains Ca (II). The problems of adopting 
a more sensitive test must be justified in view of the 
fact that no documentation exists of pyrexia follow-
ing administration of materials found apyrogenic by 
the USP test. The question of how sensitive pyrogen 
testing must be deserves further investigation. 
C. Safety. With the administration of phar-
maceuticals in radioactive form, safety includes 
radiation-absorbed doses received by target and non-
target organs that are within acceptable limits. The 
product must also be nontoxic in doses administered 
with respect to formed cells in blood as well as organs 
to which the material will be distributed. 
D. Affinity. Radioactive compounds used in 
organ imaging localize by various physiological 
mechanisms . Control of the physiochemical 
characteristics of the radiopharmaceutical are needed 
to assure affinity of the product for target organs. 
Soloway and Davis {I 0) reviewed radiophar-
maceuticals currently used for organ imaging and 
have catagorized their biological basis for localiza-
tion . In vitro quality control testing is essential to 
predetermine that organs of interest will be 
visualized. Poor affinity demonstrated by suboptimal 
images must frequently be repeated, therefore, neces-
sitating subsequent dosing with radionuclides and in-
creased radiation burden to patients. 
Perfusion lung imaging is dependant upon blood 
flow to that organ with capillary and terminal 
arteriolar blockage by radiolabeled particles. Parti-
cles for this purpose must be larger than that of red 
blood cells (7µ) to prevent arterial distribution after 
intravenous administration . To avoid an unneces-
sarily long, effective half-life in lung, as well as op-
timum patient safety, particles should be limited in 
size to 50µ. Particle size determination can be easily 
accomplished in the laboratory using light 
microscopy as a routine check. 
Images of liver and spleen are dependant upon 
blood flow to these organs with phagocytosis of 
radiocolloid by reticuloendothelial cells. Colloid of 
0.6µ and 1.0µ are necessary for localization in liver 
and spleen respectively. Although colloid may not be 
visualized by light microscopy, the test serves as a 
negative check for aggregates so large that they might 
localize in lung. 
Radioactive materials have been used to 
delineate special anatomic or biochemical compart-
ments. Labeled serum albumin has been used in the 
past for cisternography and currently for blood pool 
imaging. Care must be taken not to denature the 
protein by excessive labeling or chemical manipula-
tion. 
Stannous chloride [Sn(II)] has become a useful 
reducing agent in the preparation of technetium-
labeled radiopharmaceuticals. Yano et al (11), in 
studies with the bone imaging agent Tc99m-Sn-EHDP, 
found optimum molar ratio of Sn (II):EHDP for 
greater bone localization and rapid soft tissue 
clearance. They reported the importance in the order 
of combination of EHDP, Sn (II) and Tc99m-
pertechnetate such that poor formulation resulted in 
radiocolloid formation with localization in liver. 
Poor localization of other technetium products with 
significant uptake in thyroid has been noted when 
stannic chloride [Sn(III)] forms on crystal surfaces of 
the reducing agent. 
Physical Controls. 
A. Radioactive concentration. Refers to the ac-
tivity concentration of the product w_ith respect to ac-
tivity per unit volume. Activity concentration can be 
easily determined using a dose calibrator. This instru-
ment has an overall accuracy of 5% and is designed to 
quantitate many of the more commonly used 
radionuclides. 
B. Radioactive purity. This term should be dis-
continued in favor of the more accurate term 
"radionuclide purity." It may be defined as that 
proportion of the total activity that is present as the 
stated radionuclide. 
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The NRC limit for Mogg contamination has been 
set at I microcurie Mogg per millicuries Tcggm_per-
technetate and 5 microcuries per dose of Tcggm_ 
pertechnetate. On a milligram basis the amount of 
Mo9g necessary for a lethal dose or LD50 dose 
in test animals is large as compared to what can 
be eluted from an intact generator system (Fig. 15). 
However, on an equal activity basis using the MIRO 
system (12, 13), radiation burden from Mogg is 35 
times greater as compared to Tcggm. It has also been 
demonstrated that parent Mogg produced by neutron 
activation of Mog8 results in Cs134 contamination. 
Radioactive contaminants of Mo 99-Tc9gm 
generator systems may be detected radiometrically. 
Molybdenum-99 emits 740 and 780 kev gammas as 
well as other less energetic photons. A 4 mm lead 
shield adapter inserted in the ion chamber of the dose 
calibrator would absorb all but 0.0002% of Tc99m 
gamma (140 kev) and 50% of Mogg gamma (14). It is 
fortuitous that Mo 99 activity can be read directly on 
the Tc9gm setting when the pertechnetate source is 
placed in the lead adapter. The method allows for 
quantitation of the Mogg activity which should not 
exceed 0.1 % of the Tc99m activity. Cesium-134 emits 
605 and 796 kev gammas which penetrate the 4 mm 
lead shield and will be quantitated with the Mogg 
reading. 
In-House Preparation of Radiopharmaceuticals. 
Present day practice of nuclear medicine relies 
upon readily available organ-specific radiophar-
maceuticals. Exhaustive research of natural and man-
made radionuclides has resulted in a handful that 
demonstrate organ specificity with patient safety. As 
a result, research has been directed toward the label-
ing of molecules with radionuclides of near-ideal 
properties for organ selectivity. Technetium-99m 
having suitable physical, chemical, and biological 
properties enjoys an active role in organ imaging. 
Since 1961, many Tcg9m_labeled compounds have 
been introduced which have broadened the 
diagnostic capabilities of nuclear medicine and/ or 
improved radiation burden as compared to 
previously used radionuclides. 
Much of this research has resulted in the com-
mercial availability of kit preparations where sim-
ple asceptic techniques are employed to produce the 
desired Tcggm radiopharmaceutical. With the com-
mercial availability of Mogg-Tcggm generators, daily 
delivery, or MEK extraction techniques, a con-
tinuous supply of Tc99m-pertechnetate is at hand for 
Mo99 
Cs 134 
Toxicology of Radionuclidic Impurities in Pertechnetate 
NRC Limit - 1 µCi Mo99 / mCi 
99 
5 µCi Mo / dose 
9lln 
Tc 
99m 
Tc 
I . P. lethal dose of Mo (as No2MoO 4) in rote is about 
114 - 117 mg . Mo/ Kg. 
I. V. LD50 of Mo (as Na2 MoO 4) in mice is about 248 mg ./ Kg. 
(equivalent to 116 mg . Mo/ Kg,) 
No effect dose in mice is obout 28 mg. / Kg . 
NRC Limit - 20µCi (total body burden) 
Fig. 15-Nuclear Regulatory Commission maximum allowable 
limits for radionuclidic impurities in Tc••m-pertechnetate. 
the preparation of kits. The commercial availability 
of these tools has been a boon to many institutions 
which might not be able to provide this diagnostic ser-
vice. This availability, however, is not without cost, 
and newer formulations with clinical merit may 
take months before they become commercially 
available, thereby limiting diagnostic studies to cur-
rent available preparation. 
Radiopharmaceutical scientists (radiophar-
macist, radiochemist) have paralleled the growth of 
nuclear medicine consultants by providing efficacious 
radiopharmaceutical diagnostic agents. In-house 
preparation of radiopharmaceuticals by these in-
dividuals have allowed for the availability of newer 
agents in nuclear medicine practice. Institutions 
preparing radiopharmaceuticals are increasing, and 
those without this technical capability may benefit 
under a cost-sharing program (15). 
Several formulations are available for the 
preparation of the more routinely used imaging 
agents. The following are currently used at the 
Medical College of Virginia Hospitals . Drug-adverse 
reactions have not been reported for any of the 
products since clinical initiation. 
PREPARATION OF Tc99M-SULFUR COLLOID KIT (16) 
Solution A: 
To 100 ml of Sterile Distilled Water add: 
l. 400 mg Sodium Thiosulfate 
2. 750 mg Gelatin 
3. 850 mg Potassium Monohydrogen Phos-
phate (Dibasic) 
4. 200 mg Disodium Edetate 
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Stir and warm the mixture gently to dissolve the 
gelatin. After solution is complete, pipette ex-
actly 3 ml of the solution into each 30 ml serum 
vials. Seal the vials with rubber closures and 
aluminum caps (twice boiled in sterile distilled 
water for not less than 30 minutes and auto-
claved, wrapped in aluminum foil) and autoclave 
Solution A for 15 minutes at 20 PSIG pressure. 
Solution B: 
Sterilize 1-3 ml of exactly 0.5N HCl solution in 
serum vials by autoclaving for 15 minutes at 20 
PSIG pressure. 
Solution C: 
To 100 ml Sterile Distilled Water add: 
1. 1.20 g Sodium Hydroxide pellets 
2. 2.8 g Sodium monohydrogen phosphate 
Mix well until solution is complete. Do not 
autoclave. Sterilize by filtration using 0.22µ 
membrane filter. 
PREPARATION OF Tc99M MAA KIT (16) 
A. Prepare Albumin Sodium Acetate solution 
in distilled water such that it contains 10 
mg/ml of HSA, 100 mg/ ml of Sodium 
Acetate. Sterilize by membrane filtration 
(0.22µ size). 
B. Prepare Stannous Chloride solution in IN 
HCl such that it contains 5 mg/ml of stan-
nous chloride. Sterilize by membrane filtra-
tion (0.22µ size). 
C. To an empty sterile serum vial containing a 
small magnetic stirrer mix 5 ml of Solution A 
with 19 ml of Sterile Water for Injection. 
Mix well. Add I ml of Solution B. The pH 
should be approximately 5.5 . 
D. Macroaggregate the Albumin in the above 
solution in a water bath at 80°C± l for 12 
minutes with stirring. 
E. Cool and mix the aggregates well. Each ml 
of this preparation now contains: 
I. 2 mg HSA as aggregates (denatured) 
2. 200µg Stannous Chloride as hydroxide 
3. 20 mg Sodium Acetate as buffer 
F. Transfer under aseptic conditions 1 ml each 
of this solution to presterilized empty serum 
vials and store under refrigeration. 
PREPARATION OF Tc99M-LABELED HUMAN SERUM 
ALBUMIN ( 17) 
Materials: 
I. Kit (consists of 3 sterile pyrogen-free vials). 
Vial "A"-20 ml vial containing 0.85 ml 
of IN HCL with two I-inch lengths of Zr 
wire inserted through the diaphragm. 
Vial "B"-5 ml containing approximately 
I ml of HSA 25%. 
Vial "C"-5 ml vial containing approxi-
mately 2 ml of Sodium Bicarbonate 3.75% 
and Sodium Hydroxide 2.0% in sterile 
pyrogen-free water for injection. 
II. Lead pig (for housing 200 ml vial during 
procedure). 
III. D.C. power source with external leads 
adapted with alligator clips capable of 
providing 100 milliamps constant current 
at 3-5 volts . 
Procedure: 
I. Place vial "A" in lead pig; electrically in-
sulate the top of the container by covering 
top of lead pig and aluminum band with 
masking tape. Rubber diaphragm is left ex-
posed. 
II. To vial "A" aseptically add 5.5 ml of 
pertechnetate in normal saline (oxident 
free). Remove 5.5 ml air. 
III. To vial "A" aseptically add 0.1 ml ofHSA 
from vial "B" using a 1 ml TB syringe 
adapted with a 21 G needle. Flush syringe 
several times and remove 0.1 ml of air. 
IV. Immediately connect electrodes to power 
supply leads by means of alligator clips. 
V. Invert vial allowing contents of vial to 
come in contact with both electrodes. 
VI. Using circular motion gently agitate the in-
verted vial. Pass 100 milliamps of current 
for exactly 42 seconds; continue to agitate 
vial inverted position for an additional 15 
seconds after electrolysis is completed. 
VII . Remove leads from electrodes, reinvert vial 
to upright position and allow vial "A" to 
incubate at room temperature for at least 
30 minutes. 
VIII. Add to vial "A" 1.2 ml of vial "C". 
Remove an equivalent amount of air. 
IX. Pass the product through a 0.22µ 
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membrane filter and collect in a sterile 
empty vial. 
Radiopharmaceuticals, whether prepared in-
house or obtained commercially, should be subjected 
to quality control testing. If the limitations of image 
interpretations are instrumentation, technique, ade-
quate patient history, and radiopharmaceutical 
quality, equal attention must be payed to all. 
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Interpretation of Cerebral Dynamic Perfusion 
Studies* 
FRANK H. DELAND, M.D. 
Professor of Radiation Medicine, University of Kentucky, Lexington, Kentucky 
A review of the literature for the preceding 20 
years revea!S that by radionuclide static imaging there 
has been little improvement in the detection rate of 
cerebral lesions (l-5). The overall accuracy of brain 
scans has been reported from 81 % to 84%. For 
glioblastoma multiforme and meningioma, the detec-
tion rate is 90%-95%; for low-grade astrocytoma, 55%; 
and for ischemic strokes, from 10% to 50% depending 
on the elapsed time from the onset of symptoms. An 
aneurysm must be at least 2.5 cm in diameter and an 
arteriovenous malformation 3-4 cm in diameter 
before the information content is adequate for detec-
tion. In patients with transient ischemic attacks, 
static imaging has been unrewarding (6, 7). Why has 
there been little improvement in the detection of 
cerebral lesions by static imaging in spite of improved 
instrumentation and techniques? Visualization of ab-
normalities depends on a concentration of radioac-
tivity that is greater in the lesion than in the sur-
rounding tissue, and the mechanisms for nuclide 
concentration are similar for nearly all of the agents 
that have been used during the past 20 years. With 
few exceptions the brain-imaging radiopharmaceuti-
cals are not target specific but depend on the non-
specific changes in vascular wall integrity (for exam-
ple, dedifferentiation or focal increased intravascular 
volume, or shunts). 
There are a number of lesions that may not be 
apparent on static images, which include early 
cerebral infarctions, early subdural hematomas, con-
cussion, arteriovenous malformations of less than 
critical size for visualization, and neoplasms that are 
* Presented by Dr. DeLand at the Postgraduate Course in 
Nuclear Medicine, February 25, 1975, in Williamsburg, Virginia. 
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not sufficiently vascular or the vascular component is 
not sufficiently dedifferentiated to contribute to a 
preferential concentration of radioactivity. If 
radioactivity does concentrate in a lesion, the 
dynamic vascular character of the pathology has not 
been revealed without the appropriate study. During 
the first passage of the radiopharmaceutical, rapid se-
quential radionuclide images provide valuable infor-
mation on the dynamics of the vasculature. Rapid 
imaging increases the sensitivity of the total study 
because an increase, decrease, or no change in the 
blood flow as reflected by the radiopharmaceutical, 
has diagnostic meaning when correlated with the 
static images. Correlations are made with both ab-
normal and normal scans, and the normal scan may 
provide diagnostic information relative to the 
character of the dynamic flow studies. 
Technique. In order to obtain radionuclide im-
ages that provide the required information, precise 
attention must be given to the technique used in the 
study. The radionuclide bolus, method of in-
travenous injection, route of administration, patient 
position, and shielding-each must be given con-
sideration. 
Since the radionuclide bolus must transverse 
more than a meter of vascular channels, mix with 
blood from the inferior vena cava in the right heart, 
pass through the pulmonary capillary bed, return to 
the heart, and then be transported to the brain, a 
"tight" bolus is required; that is, less than l one ml. 
Two administrative techniques of the radionuclide 
bolus are commonly used: the Oldendorf technique 
(8) and the saline flush (9). Details of these 
procedures can be found in the original articles. 
Most commonly, intravenous materials are ad-
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NORMAL DYNAMIC FLOW 
Vertex View 
9 sec 10.5 sec 12 sec 
3637 
13.5 sec 15 sec 
Fig. IA-Early phases of normal dynamic flow (vertex). 
NORMAL DYNAMIC FLOW 
Vertex View 
18 sec 22.5 sec 25.5 sec 
28.5 sec 36 sec 
3637 
Fig. 18-Venous and recirculatory phases of normal dynamic 
flow. 
ministered in the veins of the antecubital fossa. It is 
imperative that the medial basilic vein be used 
whenever possible because this is the most direct 
route to the axillary vein. Injection into the lateral 
cephalic vein may result in: 1) delay and lengthening 
of the bolus because of the narrower caliber of the 
vessel and the right angle junction with the axillary 
vein, and 2) fractionation of the bolus because of 
anastamotic channels and the right angle junction 
(10). The Valsalva maneuver may also contribute to 
poor bolus characteristic. 
Adequate shielding of the chest and shoulders 
with lead-impregnated drapes minimizes undesirable 
activity from the heart and great vessels. During the 
9 .0 SEC 
13.5 SEC 
~ 1. 
18.0 SEC 
10.5SEC 
15.0 SEC 
21 .0 SEC 
12 .0 SEC 
16 .5 SEC 
22 .5 SEC 
Fig. 2-Nuclear angiography on 65-year-old patient being 
evaluated for seizures. 
first passage of the radionuclide bolus through the 
head, unwanted activity in the scalp can be 
eliminated by compression with a blood pressure cuff 
at the level of the external occipital protuberance and 
the forehead. When the cuff is inflated to above 
systolic pressure, the amount of radioactivity 
detected during the first transit is reduced about 15% 
to 30% (11). 
We use the vertex projection as the position of 
choice for routine cerebral dynamic perfusion 
studies. This projection will provide data on the cor-
tical distribution of most of the anterior cerebral 
artery, a portion of the posterior cerebral artery, and 
a splay of the middle cerebral artery. Not only is a 
greater area of cortex visualized, but a spread of the 
middle cerebral branches also provides greater sen-
sitivity for the detection of partial decreases in blood 
flow. Other projections are used when the clinical in-
formation dictates, particularly in patients with 
suspected subdural hematomas. 
Cases. Figure IA illustrates the early phases of a 
normal dynamic flow (vertex). At 10.5 seconds after 
intravenous administration of 99mTc04 , the activity is 
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9.0 10.5 12.0 
13.5 18.0 19.5 
21.0 28.5 STATIC 
TIME IN SECONDS 
Fig. 3-Dynamic study on patient with left cortical lesion. 
first noted in the head; at 12 seconds distribution can 
be observed in branches of the middle cerebral artery 
and early filling of the anterior and posterior cerebral 
arterial areas; further distribution in all three major 
cerebral arterial regions is demonstrated; and at the 
end of the early circulation, the cerebral cortex is per-
fused and activity is beginning to drain into the 
superior sagittal sinus. Figure l B illustrates the 
"venous" and recirculatory phases. Venous drainage 
is noted throughout the sequence. Demarcated areas 
of persistent activity are found in the superior sagittal 
sinus, torcular Herophili, and the bilateral jugular 
bulbs (36-second frame). 
Figure 2 illustrates the information that can be 
obtained from a dynamic study. The sequence was 
performed from the posterior projection. The patient, 
65 years old, was being evaluated for the recent onset 
10. 5 Sec 12.0 Se(; 
13. 5 Sec 15. 0 Sec 22894) 
Fig. 4-Nuclear angiography on 14-year-old drowning victim. 
of seizures. The primary drainage from the superior 
sagittal sinus is by the right transverse sinus with no 
venous structures observed on the left side. Although 
asymmetrical transverse sinus drainage is frequently 
encountered, displacement of the torcular Herophili 
to the right indicates an abnormality that originated 
in utero or shortly after birth. The interpretation was 
a left infratentorial fossa mass that displaced the 
venous structures to the right. Since the patient had 
been asymptomatic for 65 years, we concluded that it 
probably was a large arachnoid cyst. Cisternography 
confirmed the diagnosis. 
10.5 SEC 12 .0 SEC 13 .5 SEC 
000039 
15 .0 S.EC 16.5 SEC 
Fig. 5-Nuclear angiography on patient with head trauma. 
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22 . ~ SEC 
Fig. 6-Diminished flow of left middle cerebral artery in patient 
with right hemiparesis. 
Correlation of the sequential concentration of 
activity in a lesion with the sequential distribution of 
activity in the normal brain provides information on 
the type of pathology. For eight years a young college 
student had had muscular twitching of the right 
hand, usually precipitated by physical stress. Static 
radionuclide images revealed a left cortical lesion, 
oriented with the rolandic sulcus, in the distribution 
of the rolandic branch of the left middle cerebral 
artery. The dynamic study (Fig 3) presented the 
characteristics of a large rapid arteriovenous shunt. 
Circumscribed radioactivity was first observed in the 
left mid-hemisphere nine seconds after administra-
tion of the radiopharmaceutical. By the 12-second 
frame, activity was heavily and focally concentrated 
lQ. 5 SEC 12.0 SEC 13 .. S SEC 
9972 
15.Q SEC 16.5 SEC. 
Fig. ?-Diminished flow to left hemisphere in patient with right 
h€:.1lliparesis. 
12 sec 
21 sec 
MENINGIOMA 
13.5 sec 
•... -.. -. . j: : ~ 
" ' 
• ~ "·· +; 
31.5 sec 
16.5 sec 
8906 
Fig. 8-Dynamic study on patient with suspected arteriovenous 
malformation. 
in the left hemisphere, and early distribution to right 
cortical area was present. 
Within 1 \/2 seconds (13.5-second frame), there 
was venous drainage through the superior sagittal 
sinus. Since the 1.5-second interval was too short a 
period to attribute the venous drainage to the right 
hemispheric circulation, only a vascular shunt would 
produce this sequence of events. The diagnosis was a 
rapid arteriovenous malformation that originated 
from branches of the left middle cerebral artery and 
drained into the superior sagittal sinus. Contrast 
angiography demonstrated the arteriovenous malfor-
mation and also revealed that there was a "steal" 
from the right internal carotid blood supply by way 
of the anterior communicating artery. 
A 14-year-old boy nearly drowned and subse-
quently developed pneumonia and pulmonary 
abscesses. He became somnolent, and an electroen-
cephalogram demonstrated diffuse encephalopathy. 
In the radionuclide angiogram there was no perfu-
sion through the right middle cerebral artery with 
little evidence of collateral circulation (Fig 4). 
Angiography revealed obstruction of the internal 
carotid at the base of the skull. The absence of flow 
and collateral circulation suggested cerebral edema 
which was demonstrated by autopsy examination. 
Cerebral radionuclide angiography has been 
particularly helpful in the detection of concussion 
and contusion with associated vasospasm. For exam-
ple, a 40-year-old man received head trauma with 
contusion of the scalp on the left side. The static im-
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ages demonstrated increased peripheral activity along 
the left side that could have been a subdural 
hematoma or superficial scalp trauma. The dynamic 
study revealed irregular decreased perfusion of the 
right middle cerebral artery (Fig 5). On the basis of 
the increased superficial radioactivity on the left and 
the decreased perfusion on the right, the interpreta-
tion was contracoup concussion or contusion with 
vasospasm. Subsequent follow-up examinations did 
not demonstrate evidence of subdural hematoma, 
and the patient recovered completely. 
Radionuclide angiography has proven most 
useful in patients with cerebrovascular diseases. 
Most of our patients with strokes usually are ex-
amined within several days after the onset of symp-
toms. Although static studies are almost invariably 
negative, the dynamic studies are usually positive if 
the site of the infarction is cortical. Figure 6 il-
lustrates diminished flow of the left middle cerebral 
artery in a patient with a right hemiparesis. In addi-
tion to the localization of the decreased blood flow, 
collateral flow can frequently be evaluated and fur-
nish prognostic information. In this patient there is 
little evidence of collateral blood flow to the left 
hemisphere. The probability of his regaining function 
from this hemisphere is poor, which was borne out by 
his subsequent course. In contrast, Figure 7 il-
lustrates another patient with a right hemiparesis and 
decreased flow to the left hemisphere. In the sequen-
tial frames there is collateral blood flow to the left 
hemisphere, and this patient's prognosis is better. We 
have found a good correlation between the status of 
collateral blood flow (determined within a week after 
the stroke) and recovery of function in the affected 
side. 
As stated earlier, increased, decreased, or no 
change in perfusion does contribute to the differential 
evidence in the diagnosis of cerebral lesions. For ex-
ample, a 40-year-old man developed right-sided 
symptoms over a period of several months. The static 
images revealed an area of increased activity of the 
left cerebral hemisphere, limited to the cortex, and 
correlated with the configuration of the rolandic 
branch of the left-middle cerebral artery. From the 
static images the lesion was interpreted as a possible 
arteriovenous malformation, or as a lesser possibility, 
a progressive stroke. The dynamic study (Fig 8) 
demonstrated early concentration of radioactivity in 
the correct location that persisted through the 
dynamic sequence and did not "wash out." This 
evidence suggested a neoplasm, probably an en-
plaque meningioma that was found at subsequent 
surgery. 
The pos1t10n of cerebral radionuclide 
angiography has been well established. In our ex-
perience, 75%-85% of diagnosis from brain imaging 
is based on the dynamic studies. Improved techniques 
and continued experience with nuclide angiography 
can be expected to advance the diagnosis of central 
nervous system lesions. 
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Diagnostic Use of Radionuclides in Diseases of 
the Thyroid* 
ALTON R. SHARPE, JR., M.D. 
Professor of Radiology and Medicine, and Chairman, Division of Nuclear Medicine, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
Since the introduction of radionuclides into 
clinical medicine, a number of specific tests have been 
designed to test thyroid function and to diagnose dis-
eases of the thyroid gland. 
These studies can be broadly grouped into in 
vivo and in vitro studies. Using 1311and 1251, tests have 
been designed to measure thyroid function at the 
hypothalamic, pituitary, or thyroid level and at the 
peripheral level by radioimmunoassay or radioassay 
of circulating thyroid hormones. The following 
schema of testing may be used to assess thyroid func-
tion: 
I. Hypothalamus. Following the intramuscular administra-
tion of thyrotropic-releasing hormone, the following 
changes occur in plasma thyroid-stimulating hormone 
(TSH) level, which can be measured by radioimmuno-
assay using 12'1: 
CONDITION 
I. Normal 
2. Hyperthyroidism 
A. Toxic Diffuse Goiter 
B. Toxic Nodular Goiter 
C. Toxic Nodule 
3. Hypothyroidism 
A. Hypothalamic 
B. Pituitary 
C. Thyroid 
TSH 
Increased 
No change 
No change 
No change 
Increased 
No change 
Increased 
11. Pituitary capability of secreting TSH under normal and 
abnormal conditions can be accurately measured by de-
termination of peripheral level of TSH using 120! radio-
immunoassay techniques. The following are TSH values 
for various thyroid disorders: 
* Presented by Dr. Sharpe at the Postgraduate Course in 
Nuclear Medicine, February 27, 1975, in Williamsburg, Virginia. 
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CONDITION 
I. Normal 
2. Hyperthyroidism 
A. Toxic Diffuse Goiter 
B. Toxic Nodular Goiter 
C. Toxic Nodule 
D. Hypothalamic 
E. Pituitary Tumor 
3. Hypothyroidism 
A. Hypothalamic 
B. Pituitary 
C. Thyroid 
TSH 
l-lOµU / mlt 
Normal 
Normal 
Normal 
Increased (I) 
Increased (l) 
Low 
Normal 
Increased 
III. Assessment of thyroid glandular function can be deter-
mined by measuring the concentration of " 1! using basal 
and dynamic studies following oral administration of 1311. 
I. BASAL STUDIES PERCENT 1311 CONCENTRATION 
3 hours 5 hours 24 hours 
A. Normal Curve t2.5-l I.6% t4.l-l4.9% t9.0-3l.0% 
B. Hyperthyroid 
Curve 
C . Hypothyroid 
Curve 
2. DYNAMIC STUDIES 
>ll.6% 
< 2.5 
A. TSH Stimulation Test 
B. T-3 Suppression 
C. KClO, Discharge 
14.9% 31.0% 
4.1% 9.0% 
NORMAL R ESPONSE 
> 50% Increase 
> 50% Decrease 
< 3% Decrease 
Determination of the circulating thyroid hor-
mones by radioassay and radioimmunoassay tech-
niques using 1251 are readily available and offer accu-
rate measurement of these hormones when properly 
performed. Normal values for the circulating hor-
mones are as follows: 
t Normal values for the Medical College of Virginia. 
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l. Total thyroxine 
2. Triiodothyronine 
3. Serum free thyroxine 
5.6-13.lµg/ dlt 
70-170 ng/ dlf 
1.2-3.5 ng/ dlt 
Discussion. Differential diagnosis of diseases of 
the thyroid can be made with a high degree of cer-
tainty using the previously mentioned tests employ-
ing radionuclides. The clinical applicability of the 
various tests is dependent upon a thorough knowl-
edge of thyroid physiology and interrelationships of 
trophic hormones and carrier proteins. A review of 
the disease states and diagnosis using specific tests 
follows. 
l. Hyperthyroidism. The vast majority of cases 
can be diagnosed on clinical grounds alone from the 
history and physical findings. Confirmation is easily 
obtained by employing the 1311 uptake at 3, 5, and 24 
hours. This will be elevated in the majority of 
hyperthyroid patients. The above-mentioned test in 
conjunction with the T-4 and serum free thyroxine 
(SFT)-4, which are usually elevated, will establish the 
diagnosis in both Graves' disease and hyperthyroidism 
due to a nodular goiter. If the diagnosis is suspected 
on clinical grounds and the above tests are normal, 
one can then perform the T-3 suppression study. This 
is done by obtaining a baseline uptake at 3, 5, and 24 
hours and then placing the patient on L-
triiodothyronine, l 50µg daily for seven days. The up-
take in the normal person is suppressed after T-3 ad-
ministration by at least 50% and is usually below 20% 
at 24 hours. Hyperthyroid patients seldom suppress 
below 20% and never below 50% of original uptake. 
The usual hyperthyroid patient has little or no change 
in 24-hour uptake following T-3. Data from our 
laboratory on T-4 and SFT-4 also reveal less than 
50% suppression in the hyperthyroid patient with the 
average change being lµg/ dl or less. In rare cases, 
tl1yrotoxicosis may be due to elevated T-3 levels. 
Under these circumstances, the T-4 and SFT-4 and 
uptake are normal but the latter is nonsuppressible. 
2. Hypothyroidism. In contrast to hyperthyroid-
ism, hypothyroidism is not always easy to diagnose. 
This disease has protean manifestations and may be 
insidious in onset. 
Diagnosis when hypothyroidism is suspected 
clinically is best confirmed by a 24-hour 1311 uptake of 
less than 9% in 24 hours and a low total and free 
thyroxine of less than 5.6µg/ dl and 1.2 ng/ dl, respec-
tively. 
Differentiation between pituitary or thyroid 
failure can now be made by measuring serum TSH by 
1251 radioimmunoassay following intramuscular or in-
travenous injection of thyrotropin-releasing hormone 
(TRF). A rise in the serum TSH will occur within ap-
proximately 15 to 30 minutes after intravenous injec-
tion (2) and 2 to 3 hours after intramuscular TRF (3) 
injection if the pituitary is intact. Failure to detect a 
significant rise in TSH after TRF administration im-
plies pituitary failure and hence, establishing the 
diagnosis of secondary hypothyroidism. 
3. Subacute thyroiditis. Diagnosis of subacute 
thyroiditis is usually suggested by the clinical picture 
of anterior neck pain with exacerbation on swallow-
ing or coughing, radiation of pain to the ears, 
hoarseness, and signs and symptoms of hypermetab-
olism. The thyroid is usually enlarged and especially 
tender. 
Laboratory confirmation is established by the 
presence of a low 1311 uptake at 3, 5, and 24 hours and 
an elevated T-4 and SFT-4. 
4. Enzymatic defects. These are usually charac-
terized by the presence of a goiter dating from early 
childhood or the development of thyroid enlarge-
ment following ingestion of certain drugs or foods. 
Laboratory studies usually demonstrate an 
elevated 13 11 uptake value, low total T-4 and SFT-4 
and discharge of 131 I from the thyroid gland of greater 
than 3% following oral administration of potassium 
perchlorate or potassium thiocyanate. 
5. Nodules. Adequate assessment of both single 
and multiple nodules in the thyroid gland require that 
a scan be performed after the administration of 1311 
(4), 1251 (5) if available, or 99mTc (6). The former is 
performed in our laboratory. Evaluation of nonfunc-
tioning nodules subsequently removed surgically at 
our institution over a ten-year period reveals that 
single nonfunctioning nodules were malignant in 
12.5% of cases, multiple nodules in 16.5%, with the 
total overall incidence of malignancy being 13.0% in 
nonfunctioning nodules. (These findings have been 
noted in a study by J. M. Harrison, MD, R . H . 
Kirkland, MD, and the author, unpublished data). 
Or 24 malignant nodules out of 184 nonfunction-
ing nodules by scan. 
The incidence of malignancy in hot nodules in 
the same study was 1 out of 74, or 1.3%. Reexamina-
tion of the scan in the one case revealed that, in 
retrospect, this most likely was a cold nodule. A 
functioning nodule is thus strong evidence against 
malignancy, although some reports of this occurring 
have appeared in the literature (7) . 
The autonomous nodule with or without 
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hyperthyroidism is characterized by uptake in the 
nodule only and suppression of the remaining thyroid 
tissue. The nodule fails to suppress following the ad-
ministration of L-triiodothyronine as previously dis-
cussed and there is no significant change in the T-4 or 
SFT-4 by 1251 radioassay. Thyroid-stimulating hor-
mone and long-acting thyroid stimulator (LA TS) 
values are characteristically low for the former and 
undetectable for the latter. Autonomy can be con-
firmed by repeating the scan after administration of 
10 units of TSH. 
Conclusion. Correct assessment of thyroid func-
tion and evaluation of nodules can be obtained by the 
proper application of the appropriate in vivo or in 
vitro tests as previously discussed. Thyroid function 
can now be evaluated at the hypothalamic, pituitary, 
and thyroid level using both 1311 and 1261 and at the 
peripheral level using 1261 radioassay or radioim-
munoassay procedures. Using these procedures as 
described, quantitative evaluation of thyroid function 
can be made, and in most instances the disease 
process can be defined in a specific manner. 
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Evaluation of Thyroid Nodules-Hot and Cold* 
MELVIN J. FRATKIN, M.D. 
Assistant Professor, Departments of Radiology and Medicine, Medical College of Virginia, Health Sciences Divi-
sion of Virginia Commonwealth University, Richmond, Virginia 
Thyroid nodules occur frequently, are more 
common in women, and the incidence increases with 
age for both sexes. Clinically normal thyroid glands 
commonly contain nodules in autopsy series. In 
20- to 50-year-old females, as high as 50% of the 
thyroid glands are nodular, whereas in males the 
incidence approaches 30% (1 ). When the preva-
lence of clinically palpable thyroid nodules was the 
objective of the Framingham population researchers, 
Vander et al (2) detected nodules in 6.4% of females 
and 1.5% of males aged 30-50 years. Even with 
diligent, thorough examination of the neck, only 
about one tenth of pathologically nodular thyroid 
glands can be detected. However, the number of 
palpable nodules is significant, and determination of 
the pathology of the nodule or goiter, once found, 
rests with the patient's physician. Unfortunately, a 
detailed history and physical examination frequently 
does not provide all the necessary information 
needed to make a definite etiologic or pathologic 
diagnosis. Knowledge of the type of goiter is man-
datory for proper treatment of the various disorders 
of the thyroid gland. 
The various types or causes of goiters are shown 
in Table l. Goiters may be divided clinically into 
diffuse or nodular; hyperthyroid, euthyroid, or 
hypothyroid. It is readily apparent that several 
pathologic entities may be diffuse or nodular in addi-
tion to altering thyroid function. Hyperthyroid 
patients may have a diffuse goiter, solitary nodule, or 
a multinodular gland. Graves' disease usually pre-
sents no diagnostic problems, but, rarely, a toxic 
* Presented by Dr. Fratkin at the Postgraduate Course in 
Nuclear Medicine, February 27, 1975, in Williamsburg, Virginia. 
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diffuse goiter may be caused by excessive pituitary 
thyroid-stimulating hormone (TSH) from hypo-
thalamic thyrotropin-releasing hormone (TRH) 
stimulation or pituitary tumor. Subacute nonsup-
purative thyroiditis may be focal or diffuse and cause 
transitory hyperthyroidism. The hyperthyroid phase 
of this disease is associated with a low or blocked 
radioactive iodine uptake (RAIU) and usually a pain-
ful, hard gland. The hyperthyroid adenomatous 
goiter produces the usual findings of thyrotoxicosis 
and, clinically, a multinodular goiter. Evaluation of a 
toxic adenoma will be discussed later. 
Euthyroid diffuse goiters, with the exception of 
thyroiditis, represent compensatory enlargement of 
the gland in an attempt to maintain normal hormone 
production. Patients with dietary iodine deficiency 
have an elevated RAIU that is suppressible with 
supraphysiologic doses of thyroid hormone (our 
standard procedure is to give l 50µg daily of 
triiodothyronine for seven days). Excessive iodine in-
take is associated with a suppressed or blocked 
RAIU. Diffuse goiter from congenital thyroidal en-
zyme deficiency, that is, peroxidase deficiency, results 
in an initially elevated RAIU with discharge of 
radioiodine from the gland following potassium 
perchlorate administration. The early adenomatous 
goiter often feels diffuse rather than nodular. The 
RAIU usually is normal, but the scan often shows 
nonuniform distribution of radioactivity within the 
gland. Subacute thyroiditis may diffusely involve the 
gland, and the patient may be euthyroid when seen. 
Chronic thyroiditis (Hashimoto's thyroiditis) is a 
painless, firm goiter frequently with high titers of an-
tithyroid antibodies present in the serum. Any of the 
diffuse goiters may be accompanied by hypo-
thyroidism, but low thyroid function is more com-
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DIFFUSE 
Graves' Disease 
Excess TSH 
Thyroiditis 
TABLE 1 
Types of Goiters 
HYPERTHYROID 
EUTHYROID 
Iodine Deficiency 
Iodine Excess 
Enzymatic Defects* 
Adenomatous 
Thyroiditis* 
NODULAR 
Adenomatous 
Adenoma 
Thyroiditis 
~arcinoma 
Aden om a 
Colloid Cyst 
Adenomatous 
Thyroiditis 
* May be associated with hypothyroidism 
manly seen with congenital enzymatic deficiency 
goiters and Hashimoto's thyroiditis. 
Patients with nodular goiter (as mentioned 
earlier) may be hyperthyroid or, rarely, hypothyroid, 
but are usually eµthyroid. The euthyroid patients 
with nodular goiter, and especially those with a 
solitary nodule, represent the greatest diagnostic 
problem, for thyroid carcinoma must always be con-
sidered and excluded. Since one cannot differentiate a 
benign from a malignant tumor with certainty by 
palpation alone, further diagnostic tests are indicated 
(Fig. 1). The thyroid scan will determine whether the 
nodule is functioning (Fig. 2) or nonfunctioning (Fig. 
3). The pathology of functioning (hot) and nonfunc-
tioning (cold) nodules is shown in Table 2. The 
demonstration of a hot nodule with scanning essen-
tially excludes the probability that the lesion is a car-
cinoma. However, if the nodule is cold, one can only 
make a statistical guess concerning the pathology. 
Further diagnostic work-up can be pursued prior to 
surgical exploration (Fig. 1). Nonfunctioning, 
solitary nodules may be separated into cystic and 
solid with ultrasonography, and recent reports (3, 4) 
suggest that cystic thyroid nodules represent 20% of 
cold nodules and are benign. Additional procedures 
have been performed in an attempt to non-invasively 
exclude thyroid carcinoma. Sonography (5), in addi-
tion to distinguishing cystic from solid lesions, 
demonstrates a characteristic echo pattern in 
malignancy that may prove to be diagnostic if sub-
stantiated by additional reports. Thyroid scanning of 
cold nodules with other radiopharmaceuticals such as 
67Ga-citrate (6) and 75Selenomethionine (7, 8) may be 
positive in cases of thyroid cancer, but false negatives 
( 67Ga) and false positives (75Se) are frequent. 
Thermography (9) has been tried, but the number 
of lesions studied are too few to reach any con-
clusions. According to an oral communication 
from J. Frable, MD, in January, 1975, thin-bore nee-
dle aspiration can yield a positive diagnosis of papif-
lary adenocarcinoma, but cannot differentiate fol-
licular adenoma from adenocarcinoma. I might sum 
up by saying that the solitary, nonfunctioning and es-
pecially the solid thyroid nodule is malignant until 
proven otherwise by surgical exploration, The results 
of sonography are exciting and promising, but 
further studies are indicated before the role of 
ultrasound can be established in the evaluation of 
thyroid nodules (Fig. 4). 
The thyroid nodule that concentrates radio-
iodine may be a follicular adenoma, adenomatous 
nodule, normal thyroid tissue such as a lingual thy-
roid, or residual hyperplastic thyroid tissue following 
a subtotal thyroidectomy. The triiodothyronine sup-
pression test will differentiate the autonomously func-
tioning thyroid nodule from other types of function-
ing nodules (Fig. 5). Treatment of suppressible 
functioning thyroid nodules with thyroid hormone 
results usually in no further enlargement and fre-
quently in disappearance clinically of the nodule. 
The typical autonomously functioning thyroid 
nodule is illustrated in Figure 2. Although the patient 
is euthyroid, the nodule has suppressed the function 
of the normal thyroid tissue and is not suppressible 
with administration of triiodothyronine (Cytomel®). 
Administration of thyroid-stimulating hormone, 10 
units daily for three days, may be used to 
demonstrate the presence of normal but suppressed 
thyroid tissue. Treatment with 25 millicuries of 
radioactive iodine resulted in ablation of the nodule, 
appearance of the previously suppressed normal 
thyroid gland, and continuation of a euthyroid state. 
EVALUATION OF THYROID NODULES 
DIAGNOSTIC APPROACH 
THYRO ID NODULE 
FUNCTIONlt..JG NON-FUNCTIONING 
!c*MEd SONOGRAPHY 
SUPPRE SSED NON-SUPPRESSED SOLID CYSTIC 
Fig. I-Sequential diagnostic approach in evaluation of thyroid 
nodules. 
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Fig. 2-left. Functioning 4 X 3 cm right thyroid nodule with normal RAIU and serum free thyroxine concentration; no radioiodine 
uptake in area of left lobe. Center. Triiodothyronine (T-3) administration produced no decrease in RAIU or nodule uptake. Righi. 
Following radioiodine treatment, nodule has been ablated; right and left lobes concentrate radioiodine; overall thyroid function remains 
normal. 
.. 
" 
.. 
Fig. 3-Nonfunctioning thyroid nodule in lower pole of right 
lobe. Pathologic diagnosis was follicular adenoma. 
The question arises, though, should a nontoxic, 
autonomously functioning nodule be treated at all? 
What is the natural history of a functioning follicular 
adenoma? There are case reports of nontoxic nodules 
progressing to toxic nodules which then require 
treatment because of the development of clinical 
hyperthyroidism. Such a course of events is shown 
in Figure 6. Patient W.W. first noted a goiter 15 years 
ago, but was advised that no treatment was necessary. 
In 1969, his protein-bound iodine (PBI) was normal, 
and his nodule had gradually increased in size. 
When seen in 1973, he was hyperthyroid. Treatment 
with radioiodine achieved a euthyroid state but little 
to no reduction in the size of the nodule. It can be 
assumed that he had an autonomously functioning 
nodule from the onset that progressed in size over the 
years, achieving a sufficient mass to produce ex-
cessive amounts of thyroid hormone and hyper-
thyroidism. 
TABLE 2 
Pathology of Thyroid Nodules 
HISTOLOGIC DIAGNOSIS 
FUNCTIONING NONFUNCTIONING 
No. PERCENT No. PERCENT 
Adenomatous 
Adenoma 
Carcinoma 
Hyperplasia 
Thyroiditis, Chronic 
Unclassified 
Total 
53 
II 
0 
5 
0 
....§ 
75 
70 
15 
0 
7 
0 
8 
107 58 
31 17 
24 13 
0 0 
7 4 
.J2 8 
184 
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EVALUATION OF THYROID NODULES 
APPROACH TO TREATMENT 
I 
NON-FUNCTIONING THYROID NODULE 
I SONOGRAPHY I 
CY STI c ...... .._~-.L.I ---ii•• so LID* 
Rx: ASPIRATION + Rx: SURGERY+ 
THYROID HORMONE THYROID HORMONE 
*FURTHER EVALUATION OF NON-FUNCTIONING, SOLID 
THYROID NODULE IS INVESTIGATIONAL (1975) 
Fig. 4-Role of sonography in therapeutic approach to nonfunc-
tioning thyroid nodules. 
Is this case the exception or the rule? Horst and 
associates (IO) and later Ferraz et al (11) suggest that 
the natural history of a nontoxic but autonomously 
functioning thyroid nodule is one of progression to 
hyperthyroidism. They based their conclusions on 
data demonstrating toxic nodules being larger than 
nontoxic ones, and the rather continuous spectrum of 
functional activity from euthyroidism to overt 
hyperthyroidism. Similarly, Hamburger and Meier 
(12) noted that those patients who were hyperthyroid 
RAIU-5hr.-23% . 
F~e_e T-4 - 6.~.~9_f.dl 
Pre - Treatment 
3_-J~ -73 
, . 
EVALUATION OF THYROID NODULES 
APPROACH TO TREATMENT 
I 
FUNCTIONING THYROID NODULE 
T3 SUPPRESSION TEST 
150µg/d x 7 d 
SUPPRESSIBLE -----NON-SUPPRESSIBLE 
Rx: THYROID HORMONE 1 
TOXIC NON-TOXIC 
Rx: 1311 Rx: 131 I 
SURGERY 
OBSERVATION 
Fig. 5-Diagnostic and therapeutic approach to functioning 
thyroid nodule. 
were older and had larger nodules than euthyroid 
patients with nonsuppressible functioning nodules. In 
their prospective study of 28 nontoxic patients with 
autonomously functioning nodules followed one to 
ten years (majority followed less than six years), none 
became hyperthyroid, but four glands increased in 
size. A retrospective study by McCormack and 
Sheline ( 13) revealed 1 out of 14 nontoxic untreated 
r 
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Fig. 6-Left . Large 9 X 6 cm toxic nodule with high RAIU and serum free thyroxine concentration. Right. Establishment of normal 
function, but persistence of nodule following radioiodine treatment. 
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Fig. 7-Left. Functioning thyroid nodule in lower right lobe with partial suppression of the remainder of the gland. Right. Loss of function 
in outlined nodule. 
patients developed hyperthyroidism. The longest 
follow-up was 8 \/2 years with a mean of about 4 years. 
The available data suggest circumstantially that non-
toxic, autonomously functioning thyroid nodules 
progress to toxicity, but usually not within the first 
eight to ten years from the initial diagnosis. 
The next case (Fig. 7) illustrates the opposite 
natural history-spontaneous disappearance of func-
tion from a hot nodule. The initial scan shows a func-
tioning nodule with partial suppression of the 
remaining gland. Treatment with triiodothyronine, 
l 50µg daily for seven days, resulted in a RAIU of I%, 
and no specific therapy was instituted. The patient 
became concerned about the small but visible mass in 
her neck. When she returned nine months later, the 
nodule had lost its ability to take up radioiodine. 
Surgical exploration revealed a follicular adenoma. 
Our experience and that of others (10, 13) reveal 
that large doses of radioiodine (20-40 millicuries) are 
necessary to ablate autonomously functioning 
thyroid nodules, that euthyroid function is achieved, 
and that hypothyroidism does not develop following 
treatment when the normal thyroid tissue is protected 
by endogenous and/ or exogenous thyroid hormone. 
On occasion, a residual but nonfunctioning nodule 
may persist following radioiodine therapy. Surgery, 
although equally effective therapy (13), adds unneces-
sary additional cost and morbidity for the patient 
with an autonomously functioning thyroid nodule. 
In summary, functioning but suppressible 
thyroid nodules may be treated successfully with 
thyroid hormone (Fig. 5). Completely or partially 
autonomously functioning nodules are benign fol-
licular adenomas. This type of nodule may progress 
in size to produce hyperthyroidism or may lose its 
ability to concentrate iodine. Radioiodine is a safe, 
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efficient treatment for autonomously functioning 
thyroid nodules and should be considered the treat-
ment of choice. 
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The Diagnosis and Treatment of 
Carcinoma of the Thyroid* 
RICHARD H. KIRKLAND, M.D. 
Professor of Medicine, Medical College of Virginia, Health Sciences Division, 
Virginia Commonwealth University, Richmond 
Before going into a discussion of the diagnosis 
and treatment of carcinoma of the thyroid, I would 
like to make a few observations on the means of 
detection. 
Thyroid scanning, in my opinion, is useful only 
in the study of nodules. We see many patients who 
have had scans for diffuse thyroid enlargement, and I 
feel that in this instance, scans are useless. The basic 
reason for the scan is to discover which pieces of 
thyroid tissue have to be removed because of possible 
malignancy. I would like to emphasize, that the 
physician has to do the scan himself. He has to 
localize the nodule, properly mark it on the scan, and 
remain during the scan, as the patient may move his 
neck, thus moving the position of the nodule in 
reference to the marks. We have seen scans in the 
early days of isotope scanning where the technician, 
who was not taught to palpate the thyroid, marked 
the scan. This system is inadequate, as errors can oc-
cur. 
Using the T-3 suppression test, the criteria for 
suppression is a fall in uptake below 20% in 24 hours 
after a week on T-3, 150µ daily. However, the normal 
uptake is often below 20%, and hyperthyroid patients 
may also have less than 20% uptake, so the test is los-
ing some of its specificity. I think the criteria for the 
suppression test should be changed, or the interpreta-
tion of it, to indicate that there is "no significant" fall 
in uptake after T-3 for a week. It is very difficult to es-
tablish such criteria, because I do not know what nor-
mal figures to give. We recently saw a patient with a 
* The following is an edited transcription of a lecture presented by 
Dr. Kirkland at the Postgraduate Course in Nuclear Medicine, 
February 27, 1975, in Williamsburg, Virginia . 
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nodule who had 8% uptake in 24 hours prior to T-3. 
We went ahead with T-3 suppression, and he had 7% 
after T-3. We did not know what to do or how to in-
terpret this. We treated the patient with radioactive 
iodine, thinking that the nodule was not suppressible, 
and the other lobe did reappear on later scanning. 
This patient had an autonomous nodule with an 8.0% 
uptake. 
In my opinion, 3- and 5-hour uptakes are ab-
solutely essential. I would not want an uptake run 
only at 24-hour intervals, because we do see patients 
who have taken iodides or, unknown to us, an-
tithyroid drugs and who have normal 24-hour up-
takes but who have blocked thyroid function and are 
not making thyroid hormone at the moment. 
Therefore, it is necessary to run 3- and 5-hour up-
takes to identify this blocked type of function and, if 
diagnosis is not clear at that time, at a later 24-hour 
point. 
In the hot nodule with low radioiodine uptake 
where the T-3 suppression test may not be of great 
value, one can give TSH and do a scan afterward to 
see if the other lobe reappears. If it does reappear, in-
dications are that the nodule is an autonomous one 
which was suppressing TSH. 
I now want to discuss the diagnosis and treat-
ment of carcinoma of the thyroid. Carcinoma of the 
thyroid gland is both rare and common. It is a fre-
quent diagnosis on pathological sections, but clini-
cally it is a rare disease. Very few patients die from 
carcinoma of the thyroid. Each of us has seen so few 
thyroid carcinomas of clinical significance that it is 
difficult to gather a series sufficiently large to deter-
mine what treatment techniques are best. As some 
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evidence of the incidence, Dr. Fratkin showed that in 
one hundred cases of thyroid nodules 70% were cold. 
Of the 70% that were cold, he said 15% were car-
cinomatotis. That is a high incidence of carcinoma of 
the thyroid. Recently, a student and I went around on 
the wards at the Medical College of Virginia and felt 
every patient's thyroid regardless of what the patient 
had been admitted for. Thirty-three percent of the 
women incidentally had palpable nodular thyroid 
disease. If we take these female patients with 
nodules-70% of them cold and 15% of them with 
carcinoma-3.48% of women in the Medical College 
of Virginia should have carcinoma of the thyroid. 
Obviously these figures are not true clinically. Even 
the pathologist has problems in diagnosing thyroid 
malignancy. Thyroid-stimulating hormone stimula-
tion of the thyroid makes it so hypertrophic that 
sometimes the thyroid looks malignant although it 
doesn't behave that way. 
In patients with carcinoma of the thyroid, the 
natural course of the disease is variable, so that a 
long-term follow-up is necessary to determine what 
happens to them. One cell type, such as papillary car-
cinoma of the thyroid, might change to follicular, or 
the metastases may show at the same time different 
pathological types. Any treatment I propose, 
therefore, would have to be very arbitrary. 
I would like to mention something about the 
etiology of the carcinoma of the thyroid. Two 
Australians, Purves and Geishbach, in 1948, gave rats 
thiourea for two of their three-year life spans and 
found that 100% of the rats developed carcinoma of 
the thyroid. (This fact does not stop us from giving 
propylthiouracil to patients, and some clinics ad-
vocate this as the best treatment for 
hyperthyroidism). They stated in their article, "We 
think that the administration of thyroid extract to 
these rats would have prevented this." They gave 
thiourea to rats after. hypophysectomies and none of 
these animals developed carcinoma of the thyroid. 
This suggests to me that the etiology for the car-
cinoma, or an etiological factor, was the TSH level 
which rose in the thiourea-treated rats and stimulated 
a blocked gland. That was the first finding that led me 
to think that carcinoma might be produced by long-
term TSH stimulation of a blocked or damaged 
thyroid gland. There is also an increased incidence of 
carcinoma of the thyroid in patients who have con-
genital enzyme blocks. One type of congenital en-
zyme block is followed by nearly 100% incidence of 
carcinoma of the thyroid-another fact that makes 
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me think that TSH stimulation might lead to car-
cinoma. There is a higher incidence of carcinoma of 
the thyroid in thyroiditis where the gland may be in-
jured. The TSH may rise and the same circumstances 
occur. Irradiation of the neck in childhood is another 
etiologic factor. There are also cases of thyroid car-
cinoma which are TSH dependent. These tumors 
tend to grow more rapidly if the TSH levels are high. 
We should, therefore, keep the TSH low in patients 
who have carcinoma of the thyroid. This concept has 
been an important influence in my treatment of 
thyroid patients. Once hyperthyroidism is eliminated, 
I think anyone with thyroid disease should be on 
long-term suppressive thyroid hormones. 
These factors led me to review the histories of 
patients with carcinoma of the thyroid at the Medical 
College of Virginia in order to see if I could find a 
thyroid-damaging factor. Fifty percent of the patients 
had had some thyroid destructive disease, such as 
thyroiditis or colloid goiter, or treatment for thyroid 
suppression, such as surgery. None of them had had 
radioiodine therapy, but I think the incidence of car-
cinoma of the thyroid might increase after radio-
iodine if we live long enough to observe this course. 
How do we diagnose the carcinoma of the 
thyroid? Most cases are not diagnosed by symptoms, 
although there are some symptoms, such as 
hoarseness or a tracheal narrowing shown on AP and 
lateral x-rays. Hoarseness suggests that the recurrent 
laryngeal nerves might be invaded, and this might in-
dicate the possibility of carcinoma, especially if it is 
accompanied by a mass in the thyroid area. 
Dysphagia is suspicious. X-ray studies of the es-
ophagus showing real obstruction are helpful and do 
suggest that there is true disease present and not just 
an anxiety globus hystericus. We recently noted a 
bruit over the thyroid gland in the absence of 
hyperthyroidism. This indicated that there was high 
vascularity and suggested the possibility of 
Thyroid 
Pathology found in "hot" nodules 
Nodular colloid goiter 
Hyperplastic goiter 
Aden om a 
Carcinoma 
Unclassified 
Fig. I-Pathology in "hot" nodules at MCV. 
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8% 
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Pathology found in cold nodules ( 184) 
Nodular colloid goiter 
Chronic thyroiditis 
Adenoma 
Carcinoma 
Unclassified 
58% 
4% 
17% 
13% 
8% 
Fig. 2-i>athology is 184 cold nodules at MCV. 
malignancy. A distant metastasis might be a hint of 
carcinoma of the thyroid. If there are nodules, we 
want to do scans. If the scan shows a cold nodule, 
carcinoma is a prime possibility. Figure 1 shows the 
pathology we have seen in our "hot" nodules. 
Nodular colloid goiter was found in 70% of cases, 
hyperplastic goiter (we are not sure what the 
pathologist meant by this as these were supposedly 
nontoxic patients) in 15%, adenoma in 15%, but no 
carcinoma. Figure 2 shows the pathology in 184 cold 
nodules which were removed. Thirteen percent were 
carcinomas of the thyroid. 
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Fig. 4-0blique scan of saii-ie patient, revealing cold nodule. 
I want to emphasize the importance of lateral 
scans. Figure 3 is an AP scan of a patient who had 
had a nodule. One might think that this was a func-
tional nodule and not malignant. But on the lateral or 
oblique scan (Fig. 4), a cold nodule is seen in front of 
the radioactivity. Figure 5 shows a nodule that might 
be interpreted as a hot nodule. There is suspicion that 
it might not be a hot nodule, however, for the center 
of the gland is thicker, and one would think it would 
have a higher radioactivity. On the lateral scan, it is 
confirmed as a cold nodule . 
The treatment of carcinoma of the thyroid varies 
with the cell type, and Figure 6 sHows the main types 
of the disease. The first approach to treatment of car-
cinoma of the thyroid is surgery. The extent of the 
surgery depends on the type of lesion. A biopsy with 
a frozen section will indicate what type of malignancy 
one is dealing with. The nodule should be removed 
along with any suspect tissue, and if it is carcinoma 
on a frozen section, a total thyroidectomy is in-
dicated. The only exception would be that I would 
ask the surgeon not to take the parathyroid glands. 
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Fig. 5-Left. AP scan of possible cold nodule; Right. Confirmed on lateral scan. 
As this might be difficult, he would perform a nearly 
total thyroidectomy. Myxedema as a result of surgery 
is of no concern because the patient will be placed on 
thyroid extract. All patients with carcinoma of the 
thyroid should be on thyroid extract for the rest of 
their lives in the hope that hormonal suppression of 
the tumor will be achieved, just as one might treat 
carcinoma of the breast with appropriate hormonal 
treatment. Radical neck dissection is not often my 
choice. The surgeon usually decides this. If he feels 
that the nodes are within the range of surgical resec-
tion, he should try to get them out, but in my opin-
ion, severely disfiguring, radical neck dissection is of 
no great value. The prognosis for carcinoma of the 
thyroid is so good that, other than for anaplastic 
types, I would not urge extensive neck dissection. In a 
medullary carcinoma, there is one follow-up technique 
and that is to check on calcitonin levels, because 
this offers a marker for continuing disease. If the 
calcitonin levels were high before removal and 
afterwards fell to normal, it would be very reassuring 
that the malignancy had been completely removed. If 
calcitonin levels rose in the future, they would in-
dicate that the carcinoma had recurred and that 
further treatment should be considered. 
There is a difference of opinion regarding the 
surgical follow-up schedule. Some authors would 
wait a month and do a radioactive iodine uptake 
Classification of Thyroid Neoplasms 
A. Adenoma 
B. Carcinoma 
1. Adenoma malignum 
2. Papillary 
3. Follicular 
4. Medullary 
5. Anaplastic 
Fig. 6-Main types of thyroid disease. 
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study to see if there is any residual thyroid tissue in 
the neck. They would ablate it with radioactive iodine 
and put the patient on thyroid hormone while waiting 
to see whether the patient develops further disease. 
This seems to me unnecessary as the patient may have 
already been cured. I would put the patient on 
thyroid hormone after the initial thyroidectomy and 
wait. If disease appears, I would stop the thyroid 
replacement and do a 1311 scan. If there is uptake of 
1311 in the residual thyroid area, a thyroid ablative 
dose of 1311 should be given. In one to two months, a 
tracer dose should be given to see whether there is 
any retention of the isotope after 48 hours. At the 
Medical College of Virginia, we determine 24- and 
48-hour urinary excretions of 1311 at that stage, and if 
there is any significant retention (if the patient ex-
cretes less than 90% of the radioiodine in the urine in 
48 hours), we scan the whole body searching for areas 
of retention and treat with large doses of radioiodine. 
If there were significant retention, we would try to 
stimulate maximal uptake of radioactive iodine prior 
to treatment by giving TSH intravenously or intra-
muscularly for three days and repeat the 1311 uptake. 
Should there be increasing retention, I would keep up 
the TSH for three more days until the maximal uptake 
was reached, because this may be the only opportunity 
to get an excellent uptake in the tumor. Therefore, I 
would continue TSH until I obtained maximum 
retention of the tracer dose, then give a large dose of 
radioactive iodine (150 millicuries of radioiodine), 
hoping to obtain the maximum uptake in the tumor. 
After radioiodine had had a chance to accumulate 
in the gland, I would put the patient on triiodo-
thyronine (one of the few clinical uses for this 
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hormone in treatment) in order to suppress TSH in 
the interim, while waiting for the effect of the dose. 
The patient should be kept on that dose for about six 
weeks. The dose should then be discontinued and the 
patient retested with radioactive iodine in eight 
weeks. As long as there is uptake of radioactive 
iodine or retention of the isotope with less than 90% 
excretion in 24 hours, I would continue to treat the 
patient with radioactive iodine at approximately two-
month intervals until I had no further retention of the 
radioactive material. Of course, this has to be 
monitored by blood counts, primarily platelet counts. 
We have not seen significant platelet reduction until 
we have given 300 to 400 millicuries of radioiodine. 
Once I had achieved as much radioactive iodine treat-
ment as possible, that is, there was no longer any 
retention of the isotope 48 hours after a tracer dose, I 
would put the patient on totally suppressive and 
replacement doses of levothyroxine or triiodo-
thyronine. The triiodothyronine is used because it 
can be stopped more quickly, and its effect disappears 
more quickly. An additional method of treatment 
to consider, when radioactive treatment was no 
longer effective, would be x-ray therapy to any areas 
that were causing symptoms. 
The major point I would like to make is that we 
should try to prevent thyroid carcinoma by ad-
ministration of thyroid hormones to all patients with 
potentially high TSH and damaged-thyroid disease, 
using suppressive doses of levothyroxine. In my opin-
ion, all patients who have thyroid disease should be 
treated with thyroid hormone indefinitely, once 
hyperthyroidism has been eliminated. 
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how big a dose will now 
bring relie£if it is a narcotic? 
"Tolerance is an ever-present hazard to continued 
use of narcotics . .. . The very fi rst dose diminishes the 
effects of subsequent doses." 1 And, as increasing 
amounts of narcotics are requi red to control pa in, dis-
tressing adverse effects- lethargy, hypotension, con-
stipation, etc.-can needlessly debilitate the patient. 
l.Sadove, M. S.: A look at narcot ic and non-narcotic analgesics, Postgrad. 
Med. 49:102, June 1971. 
how big a dose will now 
bring reliei if it is Talwin? 
Chances are, the same 50 mg. Talwin Tablet you 
prescribe originally wi ll continue to provide good pain 
relief. Ta lwi n can be compared to codeine in anal-
gesic efficacy: one 50 mg. tablet appears equivalent 
in ana lgesic effect to 60 mg. (1 gr.) of codeine. How-
ever, patients receiving Ta lwin Tablets for prolonged 
periods face fewer of the consequences you've come 
to expect with narcotics. There should be fewer 
"adverse effects" on her way of life. 
Tolerance rare: Tolerance to the analgesic effect of 
Ta lwinTablets is rare. 
Dependence rare: During three years of wide clinical use, there 
have been a few reports of dependence and of withdrawal symp-
toms with orally administered Ta/win. Patients wi th a history 
of drug dependence should be under close supervision while 
receiving Ta/win orally. 
In prescribing Ta /win tor chronic use, the physician should 
take precautions to avoid increases in dose by the patient and 
to prevent the use of the drug in anticipation of pain rather 
than for the relief of pain.* 
Generally well tolerated by most patients*: Infrequently causes 
decrease in blood pressure or tachycardia; rarely causes respi-
ratory depression or urinary retention; seldom causes diarrhea 
or constipation. Acute, transient CNS effects, described in 
product information on following page, have occurred in rare 
instances fo llowing the use of Ta lwin Tablets. If dizziness, 
lightheadedness, nausea or vomiting are encountered, these 
effects may decrease or disappear after the f irst few doses. 
•see important product information on next page for adverse reactions, patient 
selection, prescribing and precautionary recommendations. 
in chronic pain 
of moderate to severe intensity -In® so mg. T.iblets 
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how big a dose will now 
bring relief if it is a narcotic? 
"Tolerance is an ever-present hazard to continued 
use of narcotics .... The very first dose diminishes the 
effects of subsequent doses."1 And, as increasing 
amounts of narcotics are required to control pain, dis-
tressing adverse effects-lethargy, hypotension, con-
stipation, etc.-can needlessly debilitate the patient. 
1.Sadove, M. S.: A look at narcotic and non-narcotic analgesics, Postgrad. 
Med. 49:102, June 1971. 
how big a dose will now 
bring relief if it is Talwill'? 
Chances are, the same 50 mg. Talwin Tablet you 
prescribe originally will continue to provide good pain 
relief. Talwin can be compared to codeine in anal-
gesic efficacy: one 50 mg. tablet appears equivalent 
in analgesic effect to 60 mg. (1 gr.) of codeine. How-
ever, patients receiving Talwin Tablets for prolonged 
periods face fewer of the consequences you've come 
to expect with narcotics. There should be fewer 
"adverse effects" on her way of life. 
Tolerance rare: Tolerance to the analgesic effect of 
TalwinTablets is rare. 
Dependence rare: During three years of wide clinical use, there 
have been a few reports of dependence and of withdrawal symp-
toms with orally administered Ta/win. Patients with a history 
of drug dependence should be under close supervision while 
receiving Ta/win orally. 
In prescribing Ta/win for chronic use, the physician should 
take precautions to avoid increases in dose by the patient and 
to prevent the use of the drug in anticipation of pain rather 
than for the relief of pain.* 
Generally well tolerated by most patients*: Infrequently causes 
decrease in blood pressure or tachycardia; rarely causes respi-
ratory depression or urinary retention; seldom causes diarrhea 
or constipation. Acute, transient CNS effects, described in 
product information on following page, have occurred in rare 
instances following the use of Talwin Tablets. If dizziness, 
lightheadedness, nausea or vomiting are encountered, these 
effects may decrease or disappear after the first few doses. 
•see important product information on next page for adverse reactions, patient 
selection, prescribing and precautionary recommendations. 
in chronic pain 
of moderate to severe intensity 
Talwrin:..~:.s 
brand of • 
pentazo(~!!!! 
in chronic 
pain of 
moderate to 
severe 
intensity 
Talwin® Tablets brand of pentazocine (as hydrochloride) 
Analgesic for Oral Use 
Indication: For the relief of moderate to severe pain. 
Contraindication: Talwin should not be administered to patients 
who are hypersensitive to it. 
Warnings: Drug Dependence. There have been instances of psy-
chological and physical dependence on parenteral Ta/win in pa-
tients with a history of drug abuse and, rarely, in patients without 
such a history. Abrupt discontinuance following the extended use 
of parenteral Ta/win has resulted in withdrawal symptoms. There 
have been a few reports of dependence and of withdrawal symp-
toms with orally administered Ta/win. Patients with a history of 
drug dependence should be under close supervision while receiv-
ing Ta/win orally. 
In prescribing Ta/win for chronic use, the physician should take 
precautions to avoid increases in dose by the patient and to pre-
vent the use of the drug in anticipation of pain rather than for the 
relief of pain. 
Head Injury and Increased lntracranial Pressure. The respiratory 
depressat')t effects of Talwin and its potential for elevating cerebro-
spinal fluid pressure may be markedly exaggerated in the pres-
ence of head injury, other intracranial lesions, or a preexisting 
increase in intracranial pressure. Furthermore, Talwin can pro-
duce effects which may obscure the clinical course of patients 
with head injuries. In such patients, Talwin must be used with 
extreme caution and only if its use is deemed essential . 
Usage in Pregnancy. Safe use of Talwin during pregnancy (other 
than labor) has not been established. Animal reproduction studies 
have not demonstrated teratogenic or embryotoxic effects. How-
ever, Talwin should be administered to pregnant patients (other 
than labor) only when, in the judgment of the physician, the po-
tential benefits outweigh the possible hazards. Patients receiving 
Talwin during labor have experienced no adverse effects other 
than those that occur with commonly used analgesics. Talwin 
should be used with caution in women delivering premature 
infants. 
Acute CNS Manifestations. Patients receiving therapeutic doses 
of Talwin have experienced, in rare instances, hallucinations (usu-
ally visual) , disorientation, and confusion which have cleared 
spontaneously within a period of hours. The mechanism of this 
reaction is not known. Such patients should be very closely ob-
served and vital signs checked. If the drug is reinstituted it should 
be done with caution since the acute CNS manifestations may recur. 
Usage in Children. Because clinical experience in children under 
12 years of age is limited, administration of Talwin in this age 
group is not recommended. 
Ambulatory Patients. Since sedation, dizziness, and occasional 
euphoria have been noted, ambulatory patients should be warned 
not to operate machinery, drive cars, or unnecessarily expose 
themselves to hazards. 
Precautions: Certain Respiratory Conditions. Although respiratory 
depression has rarely been reported after oral administration of 
Talwin, the drug should be administered with caution to patients 
with respiratory depression from any cause, severely limited res-
piratory reserve, severe bronchial asthma and other obstructive 
respiratory conditions, or cyanosis. 
Impaired Renal or Hepatic Function. Decreased metabolism of the 
drug by the liver in extensive liver disease may predispose to 
acc.entuation of siqe effects. Although laboratory tests have not 
indicated that Talw1n causes or increases renal or hepatic impair-
ment, the drug should be administered with caution to patients 
with such impairment. 
Myocardial Infarction. As with all drugs, Talwin should be used 
with caution in patients with myocardial infarction who have nau-
sea or vomiting. 
Biliary Surgery. Until further experience is gained with the effects 
of Talwin on the sphincter of Oddi, the drug should be used with 
caution in patients about to undergo surgery of the biliary tract. 
Patients ~eceiving Narcotics. Talwin is a mild narcotic antagonist. 
Some patients previously given narcotics, including methadone for 
th.e daily treatment of narcotic dependence, have experienced 
withdrawal symptoms after receiving Talwin . 
CNS Effect. Caution should be used when Talwin is administered 
to patients prone to seizures; seizures have occurred in a few such 
patients in association with the use of Talwin although no cause 
and effect relationship has been established. 
Adverse Reactions: Reactions reported after oral administration of 
Talwi~ include gastrointestinal:. nausea, vomiting; infrequently 
const1pat1on; and rarely abdominal distress anorexia diarrhea. 
CNS eftects: dizziness, lightheadedness, seda'tion, euphoria, head-
ache; 1~frequentl}'. weakness, d_istur~e~ dreams, insomnia, syn-
cope, visual blurring and focusing d1ff1cu lty, hallucinations (see 
Ac.ute .C.NS Ma.nifestatiorys t,Jnder WARNINGS); and rarely tremor, 
1rnta~1l1ty, excitement, ~1nn1tus. Autonomic: sweating; infrequently 
flu~hin~; and rarely chills. Allergic: infrequently rash; and rarely 
urt1car1'!, edema of the face. Cardiovascular: infrequently de-
crease in blood pressure, tachycardia. Hematologic: rarely de-
pression of white blood cells (especially granulocytes) usually 
rev.ersible and usually associated with diseases or oth~r drugs 
wh1~h ar.e. known to cause su.ch changes, moderate transient 
eosinoph1l1a. Other: rarely respiratory depression urinary reten-
t ion, toxic epidermal necrolysis. ' 
Dosage and Administration: Adults. The usual initial adult dose is 
1 tablet (50 mg.) every three or four hours. This may be increased 
to 2 tablets (100 mg.) when needed. Total daily dosage should not 
exceed 600 mg. 
When antiinflammatory or antipyretic effects are desired in addi-
t ion ~o analgesia, aspirin can be administered concomitantly with 
Talwin. 
Children Under 12 Years of Age. Since clinical experience in chil-
~ren. under 12 years of age is limited, administration of Talwin 
1n this age group is not recommended. 
Dura.tion of Therapy. Patients wit.h chronic pain who have received 
Talwin orally for prolonged periods have not experienced with-
qrawal symptoms even when administration was abruptly discon-
tinued (see WARNINGS) . No tolerance to the analgesic effect has 
b~en observ~d. Laboratory tests of blood and urine and of liver and 
kidney function have revealed no significant abnormalities after 
prolonged administration of Talwin . 
Overdosage: Manifestations. Clinical experience with Talwin over-
dosage has been insufficient to define the signs of this condition. 
Treatm~nt. Oxygen, intravenous fluids, vasopressors, and other 
supportive measures should be employed as indicated. Assisted 
or controlled ventilation should also be considered. Although 
nalorph1ne a".d levallorphan are not effective antidotes for respira-
tory . depression due to overdosage or unusual sensitivity to 
Talwin, P!'Jren.teral na.IC!xone (Narcan®, available through Endo 
Laboratories) 1s a spec1f1c and effective antagonist. 
Talwin is not subject to narcotic controls. 
How Supplied: Tablets, peach color, scored. Each tablet contains 
Talwin (brand of pentazocine) as hydrochloride equivalent to 
50 mg. base. Bottles of 100. 
Winthrop Laboratories, New York, N.Y. 10016 @~n7..eJ 
so mg.Tablets 
Talwin® 
brand of • pentazoc1ne (as hydrochloride) (1623MA) 
ANNOUNCING 
THE 47th ANNUAL 
McGUIRE LECTURE SERIES 
COMMON PROBLEMS IN 
DERMATOLOGY 
October 16-17, 1975 
MEDICAL COLLEGE OF VIRGINIA 
For Information Write To: 
Department of Continuing Education 
School of Medicine 
Medical College of Virginia 
Box 91 MCV Station 
Richmond, Virginia 23298 
A service to medical education from A. H. Robins: G.l 
Excerpted from Volume 2 ~;:::.. 
Of theG. I. The A. H. Robins GI. Series consists of six book- ,, - · 
lets. designed to provide a Quick, yet comprehen- : 1 • 
sive review of basic procedures and practices in S G .I. medicine - with particular emphasis on the erles physical examination as performed in the office o r ::c~ at bedside. If you have teaching responsibi lities. -,. 
on physical examination 
of the abdomen: 
Normally palpable organs: 
the edge of the liver descending, 
on inspiration, below the costal 
margin (Al: the lower pole of the 
right kidney (BJ; the abdominal 
aorta (CJ: the descending colon 
and the sigmoid (DJ: the ascend-
ing colon (El: and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease). 
Impossible to outline, unless 
diseased, distended or enlarged: 
the gallbladder, pancreas, 
stomach, small in testine, trans-
verse colon and spleen. 
limited quantities are available: Part 1 - lnspect10n. 
Part 2-Palpation, Part 3-Percussion. Part 4 - Auscultation. Part 5 -
Abdominal Pain and Part 6 - Different1al Diagnosis of Abdominal 
Disorders. Write to: The Medical Department, A.H . Robins Company. 
1407 Cummings Drive. Richmond. Virginia 23220. 
A service to medical education from A. H. Robins: 
'
~~ Excerpted from Volume 2 
oftheG.I. 
Senes 
on physical examination 
of the abdomen : 
Normally palpable organs: 
the edge of the liver descending , 
on inspiration, below the costal 
margin (A) ; the lower pole of the 
right kidney (BJ; the abdominal 
aorta (CJ; the descending colon 
and the sigmoid (DJ; the ascend-
ing colon (E); and occasionally 
the bladder (though rising of 
this organ beyond the pubis 
does not necessarily indicate 
disease). 
Impossible to outline, unless 
diseased , distended or enlarged: 
the gallbladder, pancreas, 
stomach, small intestine, trans-
verse colon and spleen. 
The A H Robins G I Series consists of six book-
lets. des1gned to provide a qu1ck . yet comprehen- · 
s1ve review of basic procedures and practices 1n 
G .1 medic1ne - w1th particular emphasis on the ' 
physical examination as performed in the office or , 
at bedside If you have teaching respons1b1l1t1es . 
l1m1ted quantities are available· Part 1 Inspectio n. 
Part 2 - Palpation , Part 3 Percuss.on. Part 4 Ausc ultat ion. Part 5 -
Abdominal Pain and Part 6 - Ddferent1at 01agnos1s o f Abdominal 
Diso rders Write to : The Medical Department. A H Robins Company. 
1407 Cummings Drive. Richmond . V1rg1nia 23 220 
each tablet. 
capsule or 5 cc. 
teag~~ful 
(23%alcohol) 
hyoscyam1ne sulfate o. 1037 mg. 
atropine sulfate 0.0194 mg 
hyoscine hydrobrom1de 0.0065 mg. 
each 
Don natal 
No 2 
01037mg 
0.0194mg. 
00065mg. 
Phenobarbital (141 gr.) 16.2 mg 
~arning may be habit forming) 
( V.. gr.)32.4mg. 
each 
Extentab 
03111 mg. 
0.0582 mg 
0.0195 mg 
C'Y. gr.) 48.6 mg. 
• B.rief summary. Adverse Reactions: Blurring of vision. dry mouth. 
d1ff1cult urination, and flushing or dryness of the skin may occur 
on higher dosage levels. rarely on usual dosage. Contraind1ca-
t1ons: Glaucoma; renal or hepatic disease. obstructive uropathy 
(for example, bladder .n.eck obstruction due to prostatic hyper-
trophy); or hypersens1t1v1ty to any of the ingredients. 
A·H·ROBI NS A H Robins Company Richmond. Virginia 23220 
each tablet. 
capsule or 5 cc. 
teaspoonful 
of elixir 
(23%alcohol) 
hyoscyam1ne sulfate O 1037 mg. 
atropine sulfate 0.0194 mg 
hyosc1ne hydrobrom1de 0.0065 mg 
each 
Don natal 
No.2 
01037mg 
00194 mg. 
00065mg. 
Phenobarbital (14 gr.) 16.2 mg 
~rning may be habit forming) 
(>;.,gr.) 32.4 mg. 
each 
Extentab 
03111 mg. 
0.0582 mg 
0.0195mg 
(o/. gr.) 48.6 mg. 
• 
• Brief summary. Adverse Reactions: Blurring of vision, dry mouth. 
difficult urination, and flushing or dryness of the skin may occur 
on higher dosage levels. rarely on usual dosage. Contraindica-
tions: Glaucoma; renal or hepatic disease. obstructive uropathy 
(for example, bladder neck obstruction due to prostatic hyper-
trophy); or hypersensit1v1ty to any of the ingredients. 
A·H·ROBI NS A H Robins Company. Richmond. Virginia 23220 
Before prescribing, please consult 
complete product information, a sum-
mary of which follows: 
Indications: Tension and anxiety 
states, somatic complaints which are . 
concomitants of emotional factors; psy-
choneurotic states manifested by tension, 
anxiety, apprehension, fatigue, depres-
sive symptoms or agitation; symptomatic 
relief of acute agitation, tremor, delirium 
tremens and hallucinosis due to acute 
alcohol withdrawal; adjunctively in skele-
tal muscle spasm due to reflex spasm to 
local pathology, spasticity caused by 
upper motor neuron disorders, athetosis, 
stiff-man syndrome, convulsive disorders 
(not for sole therapy). 
Contraindicated: Known hypersensi-
tivity to the drug. Children under 6 
months of age. Acute narrow angle glau-
coma; may be used in patients with open 
angle glaucoma who are receiving appro-
priate therapy. 
Warnings: Not of value in psychotic 
patients. Caution against hazardous 
occupations requiring complete mental 
alertness. When used adjunctively in con-
vulsive disorders, possibility of increase 
in frequency and/ or severity of grand mal 
seizures may require increased dosage of 
standard anticonvulsant medication; ,,,,,,£.....,=---<_,. 
abrupt withdrawal may be associated 
with temporary increase in frequency 
and/ or severity of seizures. Advise 
against simultaneous ingestion of alcohol 
and other CNS depressants. Withdrawal 
symptoms (similar to those with barbitu-
rates and alcohol) have occurred follow-
ing abrupt discontinuance (convulsions, 
tremor, abdominal and muscle cramps, 
vomiting and sweating). Keep addiction-
prone individuals under careful surveil-
lance because of their predisposition to 
habituation and dependence. In preg-
nancy, lactation or women of childbearing 
age, weigh potential benefit against 
possible hazard. 
Precautions: If combined with other 
psychotropics or ant icon vu lsants, con-
sider carefully pharmacology of agents 
employed; drugs such as phenothiazines, 
narcotics, barbiturates, MAO inhibitors 
and other antidepressants may potentiate 
its action. Usual precautions indicated in 
patients severely depressed, or with latent 
depression, or with suicidal tendencies. 
Observe usual precautions in impaired 
renal or hepatic function. Limit dosage to 
smallest effective amount in elderly and 
debilitated to preclude ataxia or over-
sedation. 
Side Effects: Drowsiness, confusion, 
diplopia, hypotension, changes in libido, 
nausea, fatigue, depression, dysarthria, 
jaundice, skin rash, ataxia, constipation, 
headache, incontinence, changes in sali-
vation, slurred speech, tremor, vertigo, 
urinary retention, blurred vision. Para-
doxical reactions such as acute hyper-
excited states, anxiety, hallucinations, 
increased muscle spasticity, insomnia, 
rage, sleep disturbances, stimulation 
have been reported; should these occur, 
discontinue drug. Isolated reports of neu-
tropenia, jaundice; periodic blood counts 
and liver function tests advisable during 
long-term therapy. 
® Roche Laboratories Division of Hoffmann-La Roche Inc. 
Nutley, N.J. 07110 
When, for example, despite counseling, 
tension and anxiety continue to produce 
distressing somatic symptoms 
. Promnt action 
1s a gooCl reason to 
consider Valium 
(diazepam) 
2-mg, 5-mg, 10-mg tablets 
